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 Over the past several decades, significant research has been completed in an effort to 
understand the impact Type 2 diabetes has on the expense associated with disease treatment and 
maintenance, health care industry resources, and prevention of the disease. At the same time 
many corporations have taken on the challenge of providing workplace wellness programs to 
reduce health care expense associated with chronic illness or unhealthy behaviors and improve 
the overall health of employees. Coupling these efforts with the accountable care organization 
model established via the Patient Protection and Affordable Care Act, this research determined that 
obtaining a positive return on investment for a diabetes workplace wellness accountable care organization 
is very difficult but the ability to improve participants management of diabetes is a worthy venture that 
should be continued to be evaluated to determine how program variables need to be modified to provide a 





Fourteen years ago the Institute of Medicine published Crossing the Quality 
Chasm (Institute of Medicine, 2001) that called for extensive modifications to the health 
delivery system. One of the key modifications identified in the document was “creating 
and aligning incentives for quality and increasing the transparency of quality information 
for quality improvement, accountability and consumer choice (Damberg, Raube, 
Williams and Shortell, 2005). One of the resulting innovations in the organization and 
payment for medical care has been the development of Accountable Care Organizations. 
Most recently the final ruling for Accountable Care Organizations (ACO) has specified a 
model in which provider compensation, initially for Medicare, will utilize a pay-for-
performance model. The ACO model “is meant to improve the value of health care 
services, controlling costs while improving quality as defined by outcomes, safety, and 
patient experience” (McLellan, et al., 2012) The challenge with both the pay-for-
performance and ACO model is the ability to demonstrate the reduction in cost of care by 
transitioning from episodic care models to preventive care treatment. However, recent 
innovations in computer software that aggregate medical care use and cost at the patient 
level hold promise for enabling us to identify cost reductions rapidly and with ease. 
 
While payers have been working on models to reorganize the delivery of medical 
care to focus on and reward prevention, employers have been developing sophisticated 
worksite wellness programs to change the individual worker's behavior toward disease 
prevention, in an effort to minimize the expenses associated with lifestyle decisions that 
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directly impact the cost of health insurance and health care. Many employers have 
expended significant effort to improve health and reduce expense via workplace wellness 
programs. When implemented, the majority of workplace wellness programs demonstrate 
a cost savings and a focus on lifestyle changes to improve overall health and productivity 
of employees. Participation in the programs can be voluntary or established by providing 
incentives to employees. The services provided in a workplace wellness program are very 
similar to components of effective ACO programs; utilizing disease identification, 
coordinated care, and results tracking for the improvement of individual health while 
reducing the cost of providing health care. 
  
Thus, worksite wellness programs have contributed to better employee health for 
a decade and have shown some financial benefits. However, they have been lacking in 
ability to identify the total financial benefits that they produce because they lack the 
ability to capture all medical expenditures. ACO’s are innovative structures that 
encourage evidence-based medical practice with a focus on prevention. However, most 
ACOs lack the ability to provide powerful incentives for patients to change behavior and 
have only limited resources for providing individual patient support for change. They do, 
however, have sophisticated software tools to aggregate patient utilization and cost data 
to measure the financial benefits of an increased focus on prevention.  The combination 
of a workplace wellness program with incentives and patients support structures, and the 
use of an ACO software program to capture expenditures, may enable us to measure the 
return-on-investment (ROI) for behavior change over a short (1 year) time horizon. This 
study will demonstrate how a workplace wellness program can be combined with ACO 
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software to asses ROI in the short term. We will focus this examination on a common, 
high cost condition that, when managed well, holds promise for even short-term cost 
saving. The best choice for demonstration purposes is diabetes.  
 
Diabetes, specifically Type 2 diabetes, is a disease that impacts a large percentage 
of the United States population. Either as a confirmed diagnosed disease, as an 
undiagnosed disease, or as an increased potential to develop the disease (Statistics About 
Diabetes, 2014). Significant clinical information is available to evaluate individuals with 
diabetes or those that are considered pre-diabetic. This information also provides 
guidance for appropriate disease management to maintain a healthy lifestyle mitigating 
disease progression (Diabetes Care, 2014). Although the prevalence of diabetes is well 
documented and the various degrees of the disease can be clinically diagnosed, the 
number of individuals diagnosed with diabetes has increased significantly over several 
decades (National Health and Nutrition Examination Survey). As such, the health care 
costs associated with providing care for individuals with diabetes continues to burden the 
United State health care system (American Diabetes Association, 2013). However, 
targeted interventions to change patient behavior have shown some short term financial 
benefits for patients with diabetes, which makes it an excellent disease for demonstrating 









The main research question for this study is: Can using an ACO commercially 
available software tool and a diabetes workplace wellness management program be 
combined to identify 1 year ROI in a sample of patients within an average size 
institution?  
   
If a ROI cannot be measured at 1 year, a follow-up question will be posed as 
follows: If a trend is identified, then 1) how large an increase in sample size; or 2) how 
large an increase in exposure time is recommended to have at least 80 percent power to 




 The hypothesis for this study is, “Utilizing the tools provided with both 
commercially available ACO software and workplace wellness program structure, the 
cost associated with managing the health care of individuals diagnosed with diabetes will 








REVIEW OF THE LITERATURE 
 
Diabetes the Disease 
 
 Diabetes is defined as, “a group of metabolic diseases characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action, or both.” 
(Diabetes Care, 2014) To better understand the disease, the following provides 
information on the background of diabetes, diagnosing diabetes, health conditions that 
increase the likelihood of diabetes, and historic trend of diabetes in the United States. 
 
Background of Diabetes 
 
The development of diabetes is based on two possible pathogenic processes, the 
dysfunction of the pancreas resulting in inadequate production of insulin or the abnormal 
insulin action by target tissues impacting one or more points in complex hormone action 
pathways. While both paths frequently coexist in the same patient, it is difficult to 
determine if the lack of insulin secretion or the inadequate insulin action is the direct 
cause of the disease. These two predominant pathogenic processes are categorized as 
Type 1 and Type 2 diabetes. Type 1 diabetes is specific to the dysfunction of the pancreas 
preventing appropriate secretion of insulin. Type 2 diabetes is related to the abnormal 
insulin action by target tissues.  There are other specific types of diabetes but the majority 




Symptoms of diabetes are polyuria, polydipsia, weight loss, polyphagia, and 
blurred vision. Diabetes can cause impaired growth, increased types of infections, and the 
potentially fatal conditions of ketoacidosis or nonketotic hyperosmolar syndrome. While 
both Type 1 and Type 2 diabetes present with similar symptoms, it is important to 
understand that Type 1 diabetes can be diagnosed via serological evidence that detects 
the inflammatory autoimmune condition of the pancreas or by utilizing genetic marker 
analysis but the abnormal insulin reaction of tissues associated with Type 2 diabetes may 
exist for a long period of time before presenting with clinical symptoms. Type 2 diabetes 
can be diagnosed by measuring plasma glucose after a fasting period or by A1C   
(Diabetes Care, 2014).  The pathologic response of both Type 1 and Type 2 diabetes is 
hyperglycemia, high blood sugar, which can exist in two different categories. The first 
category, prediabetes, consists of impaired glucose tolerance (IGT) or impaired fasting 
glucose (IFG). Prediabetes is the result of having elevated blood glucose levels but not to 
the level of being diagnosed with diabetes (Mayo Clinic, 2014). Prediabetes can lead to 
diabetes but can also be corrected if detected early and proper lifestyle changes of 
managing weight and participating in regular exercise are implemented. The second 
category of hyperglycemia is diabetes. Obtaining the appropriate management of blood 
glucose levels in conjunction with diabetes ranged from non-insulin therapy to insulin 








Figure 1: Disorders of Glycemia: Etiologic Types and Stages  
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*Patients presenting with ketoacidosis may return to Normoglycemia. **In rare cases patient may require 
insulin for survival (Diabetes Care, 2014).     
 
As stated previously, there are multiple types of diabetes with Type 1 and 2 being 
predominant. Type 1 diabetes accounts for 5-10% of individuals with diabetes and is 
historically known as insulin dependent diabetes or juvenile-onset diabetes. The specific 
cause of Type 1 diabetes is the result of cellular-mediated destruction of the β-cells of the 
pancreas reducing the secretion of insulin by the pancreas (Diabetes Care, 2014). Type 2 
diabetes accounts for 90-95% of individuals with diabetes and is previously described as 
the non-insulin dependent diabetes. Type 2 diabetes is directly related to an individual 
developing insulin resistance or insulin deficiency (Diabetes Care, 2014). The other types 
of diabetes (Table 1) consist of genetic abnormalities, diseases of the exocrine pancreas, 
endocrinopathies, drug or chemical induced, infections, and gestational diabetes 




Table 1: Etiologic Classification of Diabetes (Diabetes Care, 2014) 
I. Type 1 diabetes (β-cell destruction) 
A. Immune mediated 
B. Idiopathic 
II. Type 2 diabetes (insulin resistance) 
III. Other specific types 
a. Genetic defects of β-cell function 
i. MODY 3 (Chromosome 12, HNF-1α) 
ii. MODY 1 (Chromosome 20, HNF-4α) 
iii. MODY 2 (Chromosome 7, glucokinase) 
iv. Other very rare forms of MODY (e.g., MODY 4: Chromosome 13, insulin promoter 
factor-1; MODY 6: Chromosome 2 NeuroD1; MODY 7: Chromosome 9, carboxyl 
ester lipase) 
v. Transient neonatal diabetes (most commonly ZAC/HYAMI imprinting defect on 
6q24) 
vi. Permanent neonatal diabetes (most commonly KCNJ11 gene encoding Kir6.2 subunit 
of β-cell KATP channel) 
vii. Mitochondrial DNA 
viii. Others 
b. Genetic defects in insulin action 
i. Type A insulin resistance 
ii. Leprechaunism 
iii. Rabson-Mendenhall syndrome 
iv. Lipoatrophic diabetes 
v. Others 




iv. Cystic fibrosis 
v. Hemochromatosis 











e. Drug or chemical induced 
i. Vacor 
ii. Pentamidine 
iii. Nicotinic acid 
iv. Glucocorticoids 
v. Thyroid hormone 
vi. Diazoxide 
vii. Β-Adrenergic agonists 
viii. Thiazides 
ix. Dilantin 
x. γ-Interferon  
xi. Others 
f. Infections 
i. Congenital rubella 
ii. Cytomegalovirus 
iii. Others 
g. Uncommon forms of immune-mediated diabetes 
i. Stiff-man syndrome 




h. Other genetic syndromes sometimes associated with diabetes 
i. Down syndrome 
ii. Klinefelter syndrome 
iii. Turner syndrome 
iv. Wolfram syndrome 
v. Friedreich ataxia 
vi. Hunington chorea 
vii. Laurence-Moon-Biedl syndrome 
viii. Myotonic dystrophy 
ix. Porphyria 
x. Prader-Willi syndrome 
xi. Others 





Diabetes has a long term impact on the eyes, kidneys, nerves, heart, and blood 
vessels with the specific long term complications including: retinopathy that could lead to 
the loss of vision; renal failure as a result of nephropathy; peripheral neuropathy with the 
additional complications of foot ulcers, amputations, and Charcot joints; and autonomic 
neuropathy resulting in gastrointestinal, genitourinary, cardiovascular symptoms, and 
sexual dysfunction (Diabetes Care, 2014). Individuals diagnosed with diabetes could also 
experience increased rates of atherosclerotic cardiovascular disease, cerebrovascular 
disease, and peripheral arterial disease with specific comorbidities of hypertension and 
abnormal lipoprotein metabolism (Diabetes Care, 2014).   
 
Prior to 1997, a diagnosis of diabetes was based on either, fasting plasma glucose 
(FPG) greater than 140 mg/dL (7.8 mmol/L) or an oral glucose tolerance test (OGTT) 
that demonstrates an increase in blood glucose greater than 200 mg/dL. The Expert 
Committee on Diagnosis and Classification of Diabetes Mellitus issued two reports, one 
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in 1997 and a follow up report in 2003 that identified a gap in the diagnosis values that 
excluded individuals having glucose levels that are considered above normal ranges but 
not high enough to meet the diagnosis criteria for diabetes (Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus, 1997 and Genuth, Alberti, Bennett, et 
al., 2003). Based on the work of the expert committee, the individuals with glucose levels 
above the normal range but below established diabetes diagnosis ranges were classified 
as having impaired fasting glucose (IFG), which is defined by FPG levels of 100 mg/dL 
(5.6 mmol/L) to 139 mg/dL (6.9 mmol/L), or impaired glucose tolerance (IGT) with 2-h 
values in the OGTT ranging from 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L).   
 
In 2009, the Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus recommended the use of A1C to diagnose diabetes (International Expert 
Committee, 2009). A1C is a minor component of hemoglobin to which glucose is bound. 
A1C levels depend on the blood glucose concentration: The higher the glucose 
concentration in blood, the higher the level of A1C. (MedicineNet, 2014) To further 
support the use of A1C to diagnose diabetes, observational studies have provided 
evidence of a strong correlation between retinopathy and A1C (van Leiden H.A., Dekker 
J.M., Moll A.C., 2003 and Tapp R.J., Tikellis G., Wong T.Y., Harper C., Zimmet P.Z., 
Shaw J.E., 2008). In addition to observational studies, the correlation between A1C levels 
and associated complications related to diabetes has been demonstrated in controlled 
clinical trials for both type 1 (DCCT Research Group, 1995) and type 2 (Stratton, et al., 
2000) diabetes. As part of the Expert Committee’s work, an A1C level great than 6.5 was 
identified as the appropriate diagnosis level when comparing the correlation between 
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patients with retinopathy and an elevated A1C. At the time of the initial A1C 
recommendation, the Expert Committee noted that the individuals above the normal 
range but below the diagnostic indicator for diabetes (6.0 - 6.5) were at significant risk of 
developing diabetes but the range failed to identify a substantial number of patients with 
IFG and/or IGT (Diabetes Care, 2014). Subsequent research did determine that a FPG of 
110 mg/dL (6.1 mmol/L) corresponds to an A1C of 5.6 and a FPG of 100 mg/dL 
corresponds to an A1C of 5.4 (Diabetes Care, 2014) providing evidence of the A1C 
ranges that supports the diagnosis of IFG utilizing A1C.    
 
Individuals that are identified to have IFG or IGT are considered to have pre-
diabetes. The relevance of this diagnosis is anyone with IFG or IGT have a relatively 
high risk of developing diabetes in the future but implementing lifestyle changes such as 
increasing physical activity, reducing body weight by 5 – 10%, and utilizing certain 
pharmacological agents has demonstrated the delay or prevention of developing diabetes 
in people with IGT (Diabetes Care, 2014). Research by the Diabetes Prevention Program 
provides evidence that preventive interventions are effective for individuals with a mean 
A1C of above and below 5.9 (Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al., 
2002).  In addition, a systematic review of 44,203 individuals showed those with an A1C 
of 5.5 - 6.0 had a 9% to 25% risk of developing diabetes over a 5-year period and those 
with an A1C of 6.0 - 6.5 had a 20% to 25% over a 5-year period (Zhang, X., Gregg, E. 





Prevalence of Diabetes 
 
 In 2012, 29.1 million Americans had diabetes (Centers for Disease Control and 
Prevention, 2014). This is an increase of 3.3 million since the 2010 reporting period. Of 
the approximately 29 million Americans diagnosed with diabetes, 21 million were 
clinically diagnosed and the remaining individuals were identified as undiagnosed. In 
addition to the 29.1 million Americans that had diabetes, there were an additional 86 
million Americans over the age of twenty that had prediabetes in 2012 compared to 79 
million in 2010 (Statistics About Diabetes, 2014). The youth statistic, those individuals 
under twenty years old, identified roughly 280,000 Americans compared to 23,525 youth 
in 2008-2009 (Statistics About Diabetes, 2014).  Of the over 23,000 individuals under 
twenty years old with diabetes in the 2008-2009 report, 5,089 were diagnosed with type 2 
diabetes.   
 
 Further dissection of the 29.1 million adult Americans living with diabetes in 
2012, specifically percentage by age, shows that individuals sixty-five years or older 
account for 25.9% of the 29.1 million while individuals forty-five to sixty-six years old 
and twenty to forty-four years old are 16.2% and 4.1%, respectively. Evaluation by sex 
indicates that more men (13.6%) than women (11.2%) are living with diabetes (Centers 
for Disease Control and Prevention, 2014). Examination based on race and ethnicity 
yields the following composition among individuals diagnosed with diabetes: 7.6% of 
non-Hispanic whites, 9.0% of Asian Americans 9.0%, 12.8% of Hispanics, 13.2% of 
non-Hispanic blacks, and 15.9% of American Indians/Alaskan Natives (Statistics About 
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Diabetes, 2014). Asian American adult diabetes rates are further segmented into 4.4% for 
Chinese, 11.3% for Filipinos, 13.0% for Asian Indians, and 8.8% for other Asian 
Americans. Similarly, Hispanic adults are broken down by 8.5% for Central and South 
Americans, 9.3% for Cubans, 13.9% for Mexican Americans, and 14.8% for Puerto 
Ricans (Statistics About Diabetes, 2014).   
 
Comorbidities Associated with Diabetes 
 
 Based on data from 2010, diabetes is the seventh leading cause of death in the 
United States as it was listed as the underlying cause of death on 69,071 death certificates 
(Heron, 2013). It is thought that diabetes as a cause of death could be unreported as 
studies have shown that only 35% to 40% of people with diabetes had diabetes listed on 
their death certificate and only 10% to 15% had diabetes listed as the underlying cause of 
death (Statistics About Diabetes, 2014).  
 
 As mentioned previously, diabetes can increase the risk of serious complications 
such as heart disease and stroke, blindness, kidney failure, and lower-limb amputation. 
Individuals with diabetes can also experience microvascular disease such as retinopathy 
that could lead to the loss of vision; renal failure as a result of nephropathy; peripheral 
neuropathy and autonomic neuropathy (Diabetes Care, 2014). Early diagnosis of diabetes 
with proper glucose management and preventative health exams can reduce the risk or 
further development of these complications. Failure to properly manage diabetes resulted 
in 282,000 emergency room visits in 2011 that had hypoglycemia as the first diagnosis 
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and diabetes listed as an additional diagnosis. In addition, 175,000 emergency room visits 
in 2011 were associated with a hyperglycemic crisis such as, diabetic ketoacidosis and 
hyperglycemic hyperosmolar state, as the first diagnosis. Data from 2009 to 2012 
indicated that 71% of individuals diagnosed with diabetes had a blood pressure equal to 
or above 140/90 millimeters of mercury or managed their blood pressure with 
prescription medications. Data from the same timeframe also showed that 65% of adults 
diagnosed with diabetes had increased LDL cholesterol levels or were using cholesterol-
lowering medications (Centers for Disease Control and Prevention, 2014). Adults with 
diabetes were 1.7 times more likely to die from cardiovascular disease from 2003 to 
2006. During 2010, diabetics were 1.8 and 1.5 times more likely to be hospitalized for a 
heart attack and stroke, respectively. From 2005 to 2008, 4.2 million diabetics, forty 
years or older, were diagnosed with retinopathy or damage to small blood vessels in the 
retina that could result in vision loss. During this same time period, 665,000 adults with 
diabetes from the same age demographic suffered from advanced diabetic retinopathy 
that could lead to severe vision loss (Centers for Disease Control and Prevention, 2014). 
In 2011, 44% of new nephropathy or renal failure diagnoses listed diabetes as the primary 
cause. Data from 2011 also showed that 49,677 diabetics of all ages began treatment for 
renal failure and 228,924 individuals with renal failure, as a result of diabetes, were 
living on chronic dialysis or with a kidney transplant. Diabetics twenty years or older 
were about 60% of the non-traumatic lower-limb amputations in 2010. This percentage 
was equal to roughly 73,000 non-traumatic amputations (Centers for Disease Control and 




Historic Trend of Diabetes in the United States 
 
 Over the last several decades, there has been a significant increase in diabetes 
diagnosis. The Centers for Disease Control reports a 2.8% increase in diagnosed diabetes 
among U.S. Adults (Figure 2). Further research based on NHANES (National Health and 
Nutrition Examination Survey) data demonstrates a 3.8% increase in the prevalence of 
diabetes from 1988 to 2010. Specifically, the prevalence of diabetes was reported as 
follows; 5.5% with 4.6% diagnosed and 0.9% undiagnosed from 1988 - 1994, 7.7% with 
6.4% diagnosed and 1.3% undiagnosed from 1999 - 2004, and 9.3% with 8.3% diagnosed 
and 1.0% undiagnosed. The rate of prediabetes based on A1C levels of NHANES was 
5.8% in 1988 – 1994, 11.9% in 1999 – 2004, and 12.4% in 2005 – 2010 (Selvin, 































































Although a 3.8% increase in diabetes was reported over the period of 1988 – 
2004, the rate of undiagnosed diabetes remained relatively consistent. This demonstrates 
that while diabetes as a disease is becoming more prevalent in the United States, the 
diagnosis of diabetics is staying relatively consistent. When evaluating the prevalence of 
diagnosed diabetes among minorities compared with the previously reported data with 
whites, non-Hispanic blacks was 15.4%, Mexican Americans was 11.6%, and whites was 
8.6%. As expected the ethnic minority groups also had a higher prevalence of 
undiagnosed diabetes. While diabetes is not directly related to obesity, it is important to 
note that the mean BMI of the United States undiagnosed diabetes population increased 
from 21.2% in 1988 – 1994 to 32.4% in 2005 – 2010 (Selvin, Parrinello, Sacks, and 















Health Care Costs Associated with Diabetes 
 
 As stated previously, diabetes is a very complex disease that can be caused by 
many factors and a wide range of comorbidities. The following section will provide an 
overview of proper disease management, the financial impact on personal health care 
expense and quality of life, and financial impact to the health care industry. 
 
Proper Disease Management 
 
 Disease management has evolved over many decades. In 1997, Ellrodt, et al. 
defined disease management as, “programs that used a systematic approach to care and 
included more than one intervention component.”  Expansion of the idea of disease 
management has further developed the definition as the following, “Disease management 
is a system of coordinated health care interventions and communications for populations 
with conditions in which patient self-care efforts are significant. Disease management 
supports the physician or practitioner/patient relationship and plan of care, emphasizes 
prevention of exacerbations and complications utilizing evidence-based practice 
guidelines and patient empowerment strategies, and evaluates clinical, humanistic, and 
economic outcomes on an ongoing basis with the goal of improving overall health.” 




 As stated in the definition of disease management, patient self-care effort is a 
significant component of disease management. Specifically, proper disease management 
requires a patient to engage in activities and life style changes that prevent further 
exacerbation and complications of diabetes. Recommended diabetic patient self-care 
behaviors include proper nutrition therapy, exercise, glycemic control, and management 
of dyslipidemia.  
Proper nutrition therapy is focused on maintaining blood-glucose levels within 
normal range, proper lipid and lipoprotein profile management, normal blood pressure 
levels, and proper nutrition intake to prevent and treat obesity, dyslipidemia, 
cardiovascular disease, hypertension, and nephropathy (Brantle, et al., 2006). The 
specific goals and recommending body for each of the nutritional therapies are listed in 
Table 2. A key component of maintaining normal glucose levels is the monitoring of total 
carbohydrate intake in reference to postprandial glucose levels. The ability for a diabetic 
to process glucose is related to the amount of insulin available in the body. The variation 
of low and high glycemic index foods as well as the amount and type of carbohydrates 
consumed during a meal, determines the amount of insulin needed to return to a normal 
postprandial glucose level. 
Exact exercise guidelines for a diabetic, specifically aerobic and resistance 
exercise, tend to follow the general guidelines of 150 minutes of moderate-intensity or 90 
minutes of vigorous exercise per week to achieve glycemic control as well as reduce the 
risk of coronary heart disease (Zimmerman, 2013). Due to the complications associated 
with diabetes, as it relates to loss of sensation in the feet, the types of exercise should be 
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evaluated appropriately. The risk of coronary heart disease associated with diabetes is 
also an area of concern. Individuals should be screened and cleared by their health care 
provider prior to beginning any exercise programs.   
Table 2: Goals for Risk Factor Management in Patients with Diabetes (Zimmerman, 
2013) 
Risk Factor Goal of Therapy Recommending Body 
Cigarette smoking Complete cessation ADA 
Blood pressure <130/85 mm Hg 
<130/80 mm Hg 
JNC VI (NHLBI) 
ADA 
LDL cholesterol level <100 mg/dL ATP III (NHLBI), ADA 
Triglyceride level  
200-499 mg/dL 
Non-HDL cholesterol 
level <130 mg/dL 
ATP III (NHLBI) 
HDL cholesterol  
level <40 mg/dL 
Raise HDL (no set goal) ATP III (NHLBI) 
Prothrombotic state Low-dose aspirin therapy 
(patients with CHD and 
other risk factors) 
ADA 
Glucose HbA1c <7% ADA 
Overweight and obesity 
(BMI ≥ 25 kg/m2) 
Decrease BMI OEI (NHLBI) 
Physical inactivity Exercise prescription 
depending on patient’s 
status 
ADA 
Adverse nutrition  ADA, AHA, and NHLBI’s 
ATP III, OEI, and JNC VI 
ADA, American Diabetes Association; AHA, American Heart Association; ATP III, National Cholesterol Education Program 
Adult Treatment Panel III; BMI, body mass index; CHD, coronary heart disease; HDL, high-density lipoprotein; JNC VI, 
Sixth Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure; LDL, low-
density lipoprotein; NHLBI, National Heart, Lung, and Blood Institute; OEI, Obesity Education Initiative Expert Panel on 
Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. (Zimmerman, 2013) 
 
 Glycemic control, when administered properly, has the ability to reduce a 
diabetic’s A1C level. Successful glycemic management is based on an intensive 
management of insulin, blood glucose monitoring, and regular evaluations by a health 
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care provider. The Diabetes Control and Complication Trial (DCCT Research Group, 
1993) is a well-known study that demonstrated a difference between intensive and 
conventional glycemic treatment. The intensive glycemic treatment consisted of 
randomly selected study participants receiving insulin via an insulin pump or insulin 
injection three or more times per day as determined by self-monitoring of blood glucose 
three or four times per day. A health care provider saw the participants at least once a 
month. The conventional glycemic treatment consisted of randomly selected study 
participants receiving only two injections of insulin per day based on the monitoring of 
blood glucose no more than twice a day and were seen by a health provider every two or 
three months. The study resulted in an average A1C of 7.2% for the intensive treatment 
group and 9.1% for the conventional treatment group over a 6.5-year period (DCCT 
Research Group, 1993).   
 
 Management of dyslipidemia also contributes to proper disease management of 
diabetes. Specific guidelines were developed as a result of lipid-lowering trials that 
included diabetic patients and were confirmed in additional trials (Zimmerman, 2013). 
The guidelines are as follows: (1) Diabetic’s should have an LDL cholesterol level of 
<100 mg/dL, (2) If LDL cholesterol level is <100 mg/dL and triglycerides levels are 
elevated then HDL cholesterol should be <130 mg/dL, (3) Diabetic patients that have 
suffered a myocardial infarction should have an LDL cholesterol level of <70 mg/dL, and 
(4) Patients with an LDL cholesterol level, without medication of <100 mg/dL, should 




 In addition to the self-patient care requirements, individuals with diabetes need to 
establish and maintain a relationship with health care professionals that can provide 
screenings and evaluations specific to the progression of diabetes. Diabetic’s should be 
evaluated for: diabetic retinopathy to monitor eye health and establish a plan of treatment 
to avoid vision loss, diabetic nephropathy to maintain kidney health, peripheral 
neuropathy in the feet as a predecessor to the potential development of foot ulcers, and 
ischemic coronary disease as many patients with diabetes do not experience the 
associated chest pain with exertion (Zimmerman, 2013).   
 
The Financial Impact on Personal Health Care Expense and Quality of Life 
 
 In 2007, the estimated economic burden from elevated glucose levels (diagnosed 
and undiagnosed diabetes, prediabetes, and gestational diabetes (GDM)) was reported to 
be $218 billion. This amount consisted of $153 billion in increased medical costs and $65 
billion representing reduced productivity (Dall, Zhang, Chen, Quick, Yang, and Fogli, 
2010). More recent research from the American Diabetes Association estimated the total 
estimated cost of diagnosed diabetes in 2012 as $245 billion, which included $176 billion 
in direct medical costs and $69 billion in reduced productivity (American Diabetes 
Association, 2013). The 2013 study by the American Diabetes Association further 
segregated the estimated $176 billion in direct medical costs by listing the contributing 
percentages as follows: hospital inpatient care (43%), prescription medications to treat 
the complications of diabetes (18%), anti-diabetic agents and diabetes supplies (12%), 
physician office visits (9%), and nursing/residential facility stays (8%). Additional 
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research reports an increase of 48% from the burden identified in 2007. Dall et al, (2014) 
estimates the economic burden of elevated glucose levels for 2012 to be in excess of 
$322 billion consisting of $244 billion in excess medical costs and $78 billion in reduced 
productivity.  
 
 To evaluate the financial impact for individuals with diabetes, it is important to 
assess the number of people with diabetes for 2012. The CDC reports during the 2012 
time period that approximately 29.1 million people with diagnosed diabetes, 8.1 million 
with undiagnosed diabetes and 86 million prediabetic adults in the United States (Centers 
for Disease Control and Prevention, 2014). The American Diabetes Association identifies 
a 6% increase in diagnosed diabetics compared to the CDC with an estimated 22.3 
million individuals in 2012 (American Diabetes Association, 2013). The difference 
between the CDC and the American Diabetes Association is based on the prevalence 
calculations utilized and the adjustment for the prevalence of diabetes among residence in 
nursing homes. 
 
 Utilizing the population statistics provided the CDC and the American Diabetes 
Association, the national cost of diabetes by specific category is reported as $244 billion 
for diagnosed diabetes, $33 billion for undiagnosed diabetes, $44 billion for prediabetes, 
and $1.3 billion for GDM. This information, as well as a detailed individual cost by age 
is presented in Table 3. From the period of 2007 and 2012 the financial burden of 
diabetes grew by 40% for diagnosed diabetes, 82% for undiagnosed diabetes, 74% for 




Table 3: U.S. Economic Costs Associated with Diabetes and Prediabetes, by Age Group, 
2012 (Dall, et al., 2014) 
 
 
 Assessing the quality of life impact attributed to diabetes is based on several 
factors. As mentioned earlier, loss of productivity is a key impact area attributed to 
diabetes. Productivity can be measured based on absenteeism or presenteeism from work, 
inability to work, productivity reductions for those outside of the workforce, and early 
mortality. Absenteeism is defined as the number of workdays missed due to poor health. 
It has been reported that workers with diabetes average three more missed days at work 
than individuals without. Presenteeism is defined as reduced work productivity while at 
work and is reported at a greater rate than those without diabetes, ranging from 1.8% to 
38% (American Diabetes Association, 2013). Inability to work is related to the impact of 
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long-term disability as a direct result of diabetes. The CDC estimates that approximately 
65,700 lower-limb amputations are performed each year on diabetics (CDC, 2011). As 
stated previously, diabetes has the potential to impact vision and renal functionality in 
addition to lower limb amputations. All of which would have a significant impact on 
quality of life. Productivity reductions for those outside of the workforce is a measure of 
reduced time spent providing childcare, household activities, and being active in the 
community. Premature death as, it relates to diabetes, is measured by determining the 
number of premature deaths that are attributed to diabetes and calculate the expected 
future earnings (American Diabetes Association, 2013). Table 4 lists the specific data 
collected for diabetics in the United States, 2012. 
 
Table 4: Quality of Life Impact of Diabetes in the United States, 2012 (American 
Diabetes Association, 2013). 
 
Quality of Life Component     Productivity Loss 
Absenteeism 25 million days 
Presenteeism 113 million days 
Inability to Work Due to Disability 130 million days 
Reduced Productivity Outside of 
Workforce 
20 million days 
Mortality 246,000 deaths 
 
 What is not included in the data of Table 4 is the more subjective impact to 
quality of life. Individuals with diabetes have an increased risk of diabetic retinopathy, 
renal failure and lower limb medical issues that could consist of peripheral neuropathy, 
ulcers, and possibly amputations. Diabetes is also considered the leading cause of 
blindness among individuals in the twenty to seventy-four year old age range (CDC, 
2013). These health concerns will cause lifestyle modifications for the diabetic as well as 
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impact the quality of life for friends or family members serving as primary care 
providers. 
 
Financial Impact to the Health Care Industry 
 
 When considering the financial impact of diabetes, it is also important to assess 
the impact the disease has on the health care industry. Specifically, the American 
Diabetes Association (2013) has provided 2012 data (Table 5) that demonstrates how 
diabetes is attributed to health resource utilization. In the U.S. in 2012, roughly 25.7% of 
hospital inpatient days are incurred by people with diabetes. That accounts for 43.1 
million of the 168.0 total inpatient days of which 26.4 million are attributed to diabetes. 
Of the 3.6 billion outpatients care visits reported for 2012, 942.3 million are incurred by 
people with diabetes and 487.9 million are directly attributed to diabetes care. Further 
evaluation of the 2012 data shows that 8.3% of all outpatient visits, 5.7% of all 
emergency department visits, and 11.8% of medication prescriptions are associated with 
some type of diabetes care. In comparison with 2007 data, it is reported that use of 
medication attributed to diabetes has more than doubled (American Diabetes Association, 
2013).      
 
 Analyzing health resource data utilization attributed to diabetes by medical 
condition and type of service, specifically diabetes, chronic complications, and general 
medical conditions demonstrates that of the 85.7 million diagnosis codes recorded for 
physician office visits in 2012 33% were specific to diabetes, 34% were from chronic 
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complications of diabetes (neurological, peripheral vascular, cardiovascular, renal, 
metabolic, ophthalmic, and others related to diabetes), and 33% were for general medical 
conditions. Similarly, of the 7.8 million outpatient diagnosis codes reports for 2012, 39% 
were diabetes, 33% were for chronic complications of diabetes, and 28% were general 
medical (American Association of Diabetes, 2013).  
   
Table 5: Health Resource Use in the United States by Diabetes Status and Cost 
Component, 2012 (in millions of units) (American Diabetes Association, 2013) 
 
 
 Health care costs for 2012, based on the total health care expenditures for people 
with diabetes minus the projected level of expenditures that would have occurred for 
those people in the absence of diabetes, were projected to be over $1.3 trillion, of which, 
$306 billion were incurred by individuals with diabetes and $176 billion is attributed to 
the cost of diabetes. That equates to more than one in every ten health care dollars being 
attributed to diabetes (American Diabetes Association, 2013).  The greatest contributor to 
the overall health care expenditures attributed to diabetes is from higher rates of 
hospitalization admission and longer lengths of stay. It is estimated that $124 billion of 
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the projected $475 billion in hospital inpatient care is incurred by people with diabetes 
and $76 billion in national medical cost is directly related to diabetes. Similar analysis of 
medication expense shows that $77 billion of the projected $286 billion national 
medication expense is incurred by individuals with diabetes and $50 billion is attributed 
to their diabetes.  
 
 While diabetes impacts finances and quality of life for individuals and the 
resources of the health care system, it ultimately impacts all of society increasing 
insurance premiums and taxes, reduces earnings, and reduces the standard of living. 
Specifically, for the 314 million Americans in 2012, the financial burden of diabetes 
represents a hidden tax averaging over $1,000 per person in the form of higher medical 




In recent years, many organizations have identified the need to introduce 
workplace wellness programs to improve the overall health of employees, positively 
impacting employee satisfaction, and reducing the cost to provide health care insurance 
as a workplace benefit. 
 
The following section explains the difference between disease management and 
workplace wellness programs, characteristics of a successful workplace wellness 
program, and the financial and quality improvements of workplace wellness programs.   
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Disease Management and Workplace Wellness Programs 
 
As mentioned previously, “Disease management is a system of coordinated health 
care interventions and communications for populations with conditions in which patient 
self-care efforts are significant. Disease management supports the physician or 
practitioner/patient relationship and plan of care, emphasizes prevention of exacerbations 
and complications utilizing evidence-based practice guidelines and patient empowerment 
strategies, and evaluates clinical, humanistic, and economic outcomes on an ongoing 
basis with the goal of improving overall health.” (Congressional Budget Office, 2004) 
“Disease management programs are comprised of the following six components: (1) 
population identification processes, (2) evidence-based practice guidelines, (3) 
collaborative practice models to include physician and support-service providers, (4) 
patient self-management education (may include primary prevention, behavior 
modification programs, and compliances/surveillance), (5) process and outcomes 
measurement, evaluation, and management, and (6) routine reporting/feedback loop (may 
include communication with patient, physician, health plan and ancillary providers, and 
practice profiling). Full-service disease management programs must include all six 
components. Programs consisting of fewer components are disease management support 
services.” (Congressional Budget Office, 2004). 
 
Wellness programs, specifically workplace wellness programs, differ from disease 
management programs based on the fact that workplace programs are, “a coordinated and 
comprehensive set of health promotion and protection strategies implemented at the 
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worksite that includes programs, policies, benefits, environmental supports, and links to 
the surrounding community designed to encourage that health and safety of all 
employees.” (CDC, 2015) Workplace wellness programs address multiple risk factors 
and health conditions simultaneously facilitating individual employee behavior change, 
organizational culture, and worksite environment. Per the CDC (2015), workplace 
wellness programs can be divided into the following four major categories: (1) Health-
related programs defined as opportunities available to employees at the workplace or 
through outside organizations to begin, change, or maintain health behaviors, (2) Health-
related policies defined as formal or informal written statements that are designed to 
protect or promote employee health, affecting large group of employees at the same time, 
(3) Health benefits or a part of an overall compensation package including health 
insurance coverage and other services or discounts regarding health, and (4) 
Environmental supports referring to the physical factors at and nearby the workplace that 
help protect and enhance employee health. By utilizing these categories individually or in 
combination will provide the framework to further assist employees to improve current 
health or identify specific health risks that may require more specific disease 
management. 
 
Characteristics of Successful Workplace Wellness Program 
 
In reviewing the literature related to workplace wellness programs, most authors 
reference the Live for Life (Henke, Goetzel, McHugh, Isaac, 2011) program that was 
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initiated in 1979 and has been used as the basis for most workplace wellness programs 
that followed. As reported by Phillips (2009), Johnson & Johnson’s Live for Life 
program has been associated with decreased medical spending and employee health risk 
factors and an increased return of investment for the organization since 1980. Based on 
the Live for Life program and additional workplace wellness programs modeled after the 
program, six specific characteristics are associated with successful workplace wellness 
programs. First, corporate culture must introduce and maintain the wellness program as a 
benefit to the health of the individual participant and not primarily a cost savings 
measure. Second, employees and corporate leadership are dedicated to the wellness 
program and overall health improvement. Third, the program support is attributed to 
having participation-friendly corporate policies and physical environment. Fourth, the 
wellness program is not static but adaptive to the changing needs of the participants.  
Fifth, community health organizations are engaged in the wellness program and provide 
support, education, and treatment. Sixth, technology is utilized to complete health 
assessment and wellness education (Kaspin, Gorman, and Miller, 2013). In addition to 
the six characteristics associated with successful workplace wellness programs, key 
wellness interventions included are health risk assessments, lifestyle management 
activities, and behavioral programs (Kaspin, Gorman, and Miller, 2013).  
 
Health risk assessments are used to determine if individual employees may be at 
risk for conditions such as cardiovascular disease or diabetes. Generally, health 
assessments consist of biometric screenings to score specific risk factors such as 
cholesterol, A1C, body mass index, blood pressure, and tobacco use. Questionnaires may 
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be included in health risk assessments to evaluate behaviors that contribute to overall 
health condition such as diet, exercise, sleep patterns, alcohol use. Through the health 
assessment, it is possible to identify risk factors that can be addressed via lifestyle 
management (Kaspin, Gorman, and Miller, 2013). 
 
Lifestyle management consists of activities such as fitness programs and 
competitions that engage employees in becoming more active. Lifestyle management can 
also include educational programs that inform employees on health behaviors and 
provide guidance on how to integrate the behaviors into daily routines. In addition to 
fitness programs education sessions, some wellness programs may also offer health 
coaches to assist with obtaining more directed success in becoming healthier (Kaspin, 
Gorman, and Miller, 2013). Lifestyle management is a primary area of wellness programs 
that incentives are utilized to promote involvement. 
 
Behavioral health programs consist of behavior modification programs that assist 
individuals with smoking cessation, drug and alcohol addictions, and psychological 
council to address mental issues that are impacting a healthy lifestyle (Kaspin, Gorman, 
and Miller, 2013).   
 
In addition to offering the above-mentioned interventions, workplace wellness 
programs can provide incentives to encourage participation in completing health risk 
assessments, participation in lifestyle management programs, receiving preventative care 
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and for continued improvement in risk factors. Examples of the incentives are financial 
rewards, gift cards, vacations, prepaid gas cards, and electronics. Workplace wellness 
programs may also include financial assistance to minimize the impact to employees that 
are willing to improve health. This may include discounts on health insurance preventive 
premiums, preventive care coverage, and medicines (Kaspin, Gorman, and Miller, 2013).   
 
Financial and Quality Improvements of Workplace Wellness Programs 
 
 Most workplace wellness programs can demonstrate a return on investment and 
overall quality improvements to support the value of initiating a program. Johnson & 
Johnson’s Live for Life provided an annual savings of $225 per employee savings, which 
equates to an $8.55 million annual savings (Henke, Goetzel, McHugh, and Isaac, 2011). 
From 2002 to 2008, the Live for Life program was able to have a 3.7% lower than 
average annual growth in medical costs compared to a comparison group made of 
companies of similar size and in a similar industry (Kaspin, Gorman, and Miller, 2013). 
The program, in 2009, had an annual average savings of $565 per employee savings 
resulting in a return on investment ranging from 1.88 to 3.92 based on a conservative 
program cost estimate of $300 per employee. A similar review of a wellness program 
offered by Fairview Health Services reported that in 1999 the overall annual medical cost 
per employee was $4640 in 1999. For the time period the 1999 cost per employee was 
almost $1000 higher than the national healthcare averages. Each year of the program had 
a cost savings per employee culminating in 2003 with a savings of $282 per employee. In 
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2004 the average cost for health care per employee for Fairview Health Services was 
$6511, which was $200 per employee below the national average for the industry 
(Fairview, 2006). Naydeck reported in 2008 that the Highmark Health Tracks and Extra 
Mile workplace wellness program participants had a $176.47 per employee lower health 
care costs when compared to the nonparticipant group (Naydeck, Pearson, Ozminkowski, 
Day, and Goetzel, 2008). Providence General Medical Center’s was able to reduce their 
monthly medical claims by 24% and saved over $2 million over a six year period 
(Providence, 2000).   
 
 In addition to evaluating overall health care cost savings, several studies reported 
decreases in health insurance premiums (Kaspin, Gorman, and Miller, 2013). In 2007, 
Cable reported that the Highsmith wellness program impacted health insurance premiums 
by incurring a 4.6% premium increase over a five year period while health care costs for 
United States employers increased 60% during the same period. A study completed by 
the Oswald Company, reported that companies with workplace wellness programs had 
insurance premiums $1030 per employees less than similar companies without wellness 
initiatives (Sammer, 2006). Redstone’s workplace wellness program saw an 8% decrease 
in health care premiums in the first year of the program (Hodge, 2006). 
 
 Indirect health care costs were also reported as a positive impact workplace 
wellness programs (Kaspin, Gorman, and Miller, 2013). One study reported a decrease of 
20% in workers compensation costs that had a wellness coach located at the facility for a 
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year or longer. The same study also reported 75% fewer lost workdays annually for 
locations that participated in wellness program activities (Abt, 2009). Both the 
Providence and Highsmith workplace wellness programs resulted in a reduction of lost 
work time by reporting a 37% annual reduction in sick time and a one third to one half 
reduction in the annual absenteeism rate, respectively (Providence, 2000 and Cable, 
2007).  
 
 The top four categories of health quality improvements reported across twenty 
separate workplace wellness programs were, increased exercise level, health risk 
reduction, smoking cessation, and decreased blood pressure (Kaspin, Gorman, and 
Miller, 2013). Participants in Live for Life program offered by Johnson & Johnson 
experienced decreased health related risks for high blood pressure (4.1% lower), high 
cholesterol (0.3% lower), poor nutrition (6.7% lower), obesity (6.6%), physical inactivity 
(0.7% lower), and tobacco use (10.6% lower) (Henke, Goetzel, McHugh, and Isaac, 
2011). Highsmith employees in the high-risk category for cholesterol improved by 66% 
and overall health measurements and blood pressure improved (Cable, 2007). Con-way 
Freight’s workplace wellness program resulted in 831 employees losing a combine total 
of 6,269 pounds, 170 employees quitting smoking, 669 employees reduced hypertensive 
blood pressure levels, almost 1,470 employees successfully lowered blood pressure 
through exercise and proper diet, and over 5,300 employees benefited from a total of 





The Patient Protection and Affordable Care Act 
 
 
 The Patient Protection and Affordable Care Act was signed by President Barack 
Obama, March 23, 2010 with the goal of improving access to affordable health care. 
Initial analysis of the 906-page act estimated that 95% of all Americans would be 
insured, providing insurance coverage to an additional 32 million citizens (Healthcare 
Reform, 2011). The following analysis of the Patient Protection and Affordable Care Act, 
outlines the: (1) policy options that lead to the final law, (2) identification of proponents 




 Health care reform is a significant public policy debate that many presidents have 
attempted to address during their time in office (Hartung, 2012). During the 2008 United 
States presidential election, Senator Barak Obama, campaigned on the platform that the 
cost of health care was a threat to the United States economy and that health care should 
be a right for every American (Healthcare Reform, 2011). After winning the 2008 United 
States presidential election, President Barak Obama challenged Congress to create a 
health care reform bill based on eight principles (President’s Plan for Health Care, 2009): 
 
1. Reduce long-term growth of health care costs for businesses and government 
2. Protect families from bankruptcy or debt because of health care costs 
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3. Guarantee choice of doctors and health plans 
4. Invest in prevention and wellness 
5. Improve patient safety and quality of care 
6. Assure affordable, quality health coverage for all Americans 
7. Maintain coverage when you change or lose your job 
8. End barriers to coverage for people with pre-existing medical conditions. 
 
In response to President Obama’s challenge the U.S. House of Representatives 
approved the Affordable Health Care for America Act (HR 3962) with a vote of 220-215. 
While House Democrats predominantly supported the bill, 39 Democrats voted against 
the bill and only 1 Republican voted in favor of the bill (Clerk of the U.S. House of 
Representatives, 2009). The estimated impact of the proposed bill was; (1) a cost of over 
$1.1 trillion dollars, (2) provide coverage for 36 million uninsured Americans, (3) create 
a government health insurance program, and (4) reduce the federal deficit by $118 billion 
dollars over a nine-year period (Healthcare Reform, 2011).  
 
The Senate approved Patient Protection and Affordable Care Act (HR 3590), in a 
60-39 party-line vote in response to health care reform challenge from President Obama 
(U.S. Senate Roll Call Votes, 2009). Interestingly, bill HR 3590 was originally passed in 
the U.S. House of Representative as the Service Members House Ownership Tax Act of 
2009, which modified the home buyer’s credit for members of the Armed Forces and 
certain Federal Employees (Healthcare Reform, 2011). The original bill had nothing in 
common with health care reform but was co-opted by the Senate, changing the existing 
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language, to become the Patient Protection and Affordable Care Act. The Senate took this 
approach because the Constitution requires all revenue-based bills to start in the House of 
Representatives and the proposed Senate bill on healthcare reform involved revenue 
(GovTrack, 2013). Senate Republicans argued that the bill was unconstitutional, 
socialistic, and too costly and would increase the cost of health insurance for those 
already insured. The estimated impact of the Patient Protection and Affordable Care Act 
was; (1) a cost of $871 billion dollars, (2) provide coverage for 31 million uninsured 
Americans, (3) would require the majority of Americans to have health insurance, and (4) 
reduce the federal deficit by $138 billion dollars over a nine-year period (Healthcare 
Reform, 2011). Figure 3, provides a detailed comparison of the House and Senate bills. 
 
 
Figure 3: Comparison of the Patient Protection and Affordable Care Act (HR 3590) to 
the Affordable Health Care for America Act (HR 3962) – December 24, 2009 
SOURCE: Side-By-Side Comparison of Major Health Reform Proposals, Henry J. Kaiser Family Foundation (2009). 
 
 Similarities Difference 
Public Option 
Both create Health 
Insurance/Benefit Exchanges, 
which governments may 
administer, where individuals and 
employers can purchase coverage. 
Both have restrictions on coverage 
for abortion beyond what is 
permitted by federal law (to save 
the life of the woman and in cases 
of rape and incest).  
HR 3962: Creates the Health 
Insurance Exchange, where a 
public insurance option is offered. 
States may operate their own 
Exchanges. Access to the 
exchange is limited to all 
individuals who do not already 
have coverage through individual, 
employer, or government 
insurance. 
HR 3590: Requires at least two 
multi-state plans in each 
Exchange, one of which must be a 
non-profit. Access to the health 
insurance exchanges is limited to 
U.S. Citizens and legal 




Both require individuals to have 
qualifying health coverage, and 
both penalize those without 
coverage, with exemptions for 
religious objections and financial 
hardship.  
HR 3962: Penalty is equal to 2.5% 
of adjusted income up to the cost 
of the average national premium 
for coverage under a basic plan in 
the Exchange, effective 2013.  
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 HR 3590: Penalty is equal to 
$750/year for individuals and up 
to $2,250 for families. Penalty is 
phased-in starting in 2014.  
 
Employer Mandate 
Both assess penalties on employers 
who do not offer health care 
coverage to their employees.  
HR 3962: Penalty for not offering to 
contribute at least 72.5% of 
premium cost of coverage (65% for 
families) is equal to 8% of payroll 
for employers with payroll of $750k 
or more; penalties are phased in for 
employers with $500 - $750k, 
exempt for employers with payroll 
of less than $500k. Automatic 
enrollment into lowest-cost plan for 
all employees. Report on impact of 
employer responsibility 
requirements to consider whether an 
employee hardship exemption is 
appropriate due by 1/1/12. 
HR 3590: No penalty is assessed for 
employers with less than 50 
employees/employers whose 
employees do not receive insurance 
exchange tax credit. Lesser of 
$3,000 per employee receiving 
coverage subsidy or $750 penalty 
per full-time employee if at least 
one employee receives coverage 
subsidy in a business with 50+ 
employees. Fee of $400 for any full-
time employee on which a 30-60 
day waiting period for coverage is 
imposed and $600 for a 60-90 day 
waiting period. Employers with 
200+ employees automatically 
enroll employees into health plans 
(employees may opt out). 
Individual Subsidies 
Both offer subsidies to low- and 
middle-income individuals and 
families on a sliding scale up to 
400% of the Federal Poverty Level. 
Both allow individuals to seek 
subsidies if their employer offers 
health premiums above a threshold 
percentage of income. Both limit 
subsidies to U.S. citizens and legal 
immigrants. Both restrict use of 
subsidies for coverage of abortion 
that goes beyond what is federally 
permitted. 
HR 3962: Employer premium 
threshold is 12% of income. 
Subsidies are effective January 1, 
2013. Establishes sliding scale 
limits on out-of-pocket spending. 
HR 3590: Employer premium 
threshold of 9.8% of income. 
Subsidies are effective January 1, 
2014. 
Employer Subsidies 
Both offer subsidies to employers 
with less than 25 employees and 
average annual wages of less than a 
specific threshold. Both offer a 
temporary reinsurance program for 
employers providing health 
insurance coverage to retirees over 
the age of 55 that are not eligible of 
Medicare. Both reinsurance 
programs reimburse employers for 
80% of retiree claims between 
$15K-$90K, which will be used to 
HR 3962: Average annual wage 
threshold is below $40K. Subsidy is 
provided for no more than two 
years. Offer 50% credit of premium 
costs paid by employers who have 
less than 10 employees or average 
annual wages of less than $20K. 
Effective 2013. Appropriates $10 
billion for the reinsurance program. 
HR 3590: Average annual wage 
threshold is below $50K. Starts of 
offering up to 35% credit for 
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lower the costs for enrollees in the 
employer plan. 
employer’s premium costs paid if 
employer contributes at least half of 
the premium cost, phases in up to 
50%. Full credit available to    
employers with less than 10 
employees and average annual 
wages of less than $25K and phases 
out as firm size and average wage 
increases. Appropriates $5 billion 
for the reinsurance program. 
Financing Reform 
Both make cuts to Medicare and 
Medicaid payments. Impose fees 
on medical device makers, collect 
fines from individuals and 
employers that do not obtain/offer 
health care coverage, prohibit 
reimbursement of non-prescribed 
drugs through health savings 
accounts, and increase tax on 
health savings distributions that are 
not used for qualified medical 
expenses.  
HR 3962: Income tax of 5.4% of 
gross income on individuals making 
$500K/couples making $1M 
annually. 
HR 3590: Excise tax on health plans 
with value of $8,500 for individuals 
and $23,000 for families. $2.3B 
annual tax on pharmaceuticals, $2B 
tax on medical device makers, $2B 
on health insurance sector (increases 
to $10B by 2017). 10% tax on 




Both establish a temporary high-
risk pool to provide coverage to 
individual with pre-existing 
conditions that have not been 
insured for at least six months 
prior. Both prohibit private 
insurance companies from denying 
coverage or charging higher 
premiums because of a person's 
medical history. Both prohibit 
lifetime limits on coverage. Both 
would strip private insurance from 
antitrust exemptions.  
 
HR 3962: Requires medical loss 
ratio of no less than 85%. Children 
up to 27 years old have access to 
dependent coverage. Removes 
anti-trust exemption for health 
insurers and medical malpractice 
insurers.  
HR 3590: Requires medical loss 
ratio of no less than 80% for 
individual and small group 
markets and 85% for all others. 
Children up to 26 years old have 
access to dependent coverage. 
Prohibits waiting periods of 
coverage of more than 90 days. 
Limit deductibles for individuals 
to $2k, $4k for families.  
 
Prevention/Wellness 
Both create task forces to develop, 
update and disseminate evidence-
based recommendations on the use 
of clinical and community 
prevention services and offer grants 
to fund these efforts. Both cover 
proven preventive services and 
eliminates cost sharing for 
preventive services in Medicare 
and Medicaid. Both require chain 
restaurants and food sold from 
vending machines to disclose 
nutritional content. Both offer 
grants to employers for offering 
wellness programs to its 
employees.  
HR 3962: Grants available to 
community health workers to 
promote positive, healthy lifestyles 
in underserved communities and 
grants to plan and implement 
programs to prevent obesity.  
HR 3590: Requires qualified 
health plans to provide coverage of 
effective preventive services.  
 
Improvements to Health 
System Performance 
Both support comparative 
effectiveness research with 
establishment of institutes; seek to 
explore alternatives to medical 
liability laws; create Independence 
at Home demo program to provide 
HR 3962: Strengthens financial 
support to primary care providers; 
enact studies on geographic 
variation adjustments for Medicare 
payments; conduct study on 
Medicare payments for English 
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high-need Medicare patients with 
primary care services in their home 
and allow providers to share in 
cost-savings associated with 
reduced hospital admissions; 
improve care coordination for 
dually eligible; expand Medicaid 
and CHIP Payment and Access 
Commission to include adults; 
establish best practices for health 
care delivery; require disclosure of 
financial relationships between 
health entities, enhance collection 
and reporting of data on race, sex, 
primary language, and disability 
status.  
language assistance. Increases 
Medicaid payments for primary care 
(cont.) providers to 100% of 
Medicare rates.  
HR 3590: Pays hospitals based on 
performance on quality measures; 
establishes pilot program for 
bundled payments.  
 
Expansion of Public 
Programs 
Both would expand Medicaid 
eligibility and federal government 
would pick up the cost of 
expansion for at least two years, 
eventually moving to a federal-
state shared funding plan.  
HR 3962: Medicaid expanded to 
all individuals under the age of 65 
with incomes up to 150% of the 
Federal Poverty Level. Federal 
government would pick up full 
cost of expansion from 2013 - 
2014. Afterwards, federal 
government would pay 91% and 
states pick up the remaining 9%. 
Repeals Children’s Health 
Insurance Program (CHIP) and 
requires enrollees to instead enroll 
in the Exchange. If children have 
below 150% of the Federal 
Poverty Level, they may remain 
enrolled in Medicaid.  
HR 3590: Medicaid expanded to 
all individuals under the age of 65 
with incomes up to 133% of the 
Federal Poverty Level. Federal 
government would fully finance 
expansion for three years. 
Maintains CHIP, with a planned 




Both simplify health insurance 
administration by setting standards 
for financial and administrative 
transactions; reduce payments to 
Medicare Advantage plans and 
offer bonus payments for higher-
quality plans; reduce payments to 
Disproportionate Share Hospitals; 
create innovation centers to test 
more efficient service delivery 
models; reduce Medicare payments 
to hospitals for preventable 
readmissions, prohibit federal 
payments to state for services 
related to health care acquired 
conditions; increase Medicaid drug 
rebate percentage to 23.1% (from 
15.1%); authorize FDA to approve 
generic versions of drugs.  
HR 3962: Require drug 
manufacturers to provide rebates 
for dually eligible; Secretary to 
negotiate drug prices directly with 
manufacturers; halt agreements 
between brand name and generic 
manufacturers that obstruct 
competition from generic 
drugs. HR 3590: Penalty of $1 per 
covered life for those health plans 
that do not document compliance 
with finance/admin standards; 
eliminate the Medicare 
Improvement Fund; develop 
database capture/share data across 
federal/state programs, increase 
penalties for submitting false 
claims, increase funding for anti-





Both are estimated by the 
Congressional Budget Office to 
reduce the federal budget deficit by 
over $100B over ten years.  
 
HR 3692: Congressional Budget 
Office estimates that the net cost 
of the proposal to be $894B over 
ten years. Net savings from 
Medicare and Medicaid are 
estimated at $426B over ten years. 
The largest source of revenue 
($461B over ten years) would 
come from a 5.4% tax on families 
with incomes over $1M and 
individuals with incomes over 
$500k.  
HR 3590: Congressional Budget 
Office estimates that the cost of 
coverage components of the 
proposal to be $871B over ten 
years. Net savings from Medicare 
and Medicaid are estimated at 
$438B over ten years. Largest 
source of revenue from excise tax 
on high-cost insurance, amounting 




 There are several similarities between HR 3962 and HR 3590 but some of the key 
differences are: (1) HR 3590 was proposed to be phased in starting in 2014 instead of 
2013; (2) HR 3590 established compliance thresholds for employers that have less than 
50 employees; (3) HR 3962 proposed financing health care reform by applying a 5.4% 
gross income tax on individuals making more than $500,000 or families making more 
than $1,000,000 annually. HR 3590 proposed financing health care reform by applying 
an excise tax on “Cadillac” health care plans, pharmaceutical companies, medical device 
makers, and the insurance sector; (4) HR 3590 proposed paying hospitals based on 
performance and quality measures; (5) the cost of HR 3692 would be fully funded by the 
federal government the first year and then shift to 91% federal / 9% state matching 
model. HR 3590 would be covered 100% by the federal government for the first three 
years; and (6) HR 3590 proposed a net savings for Medicare and Medicaid of $438 
42 
 
billion dollars over ten years. HR 3962 proposed a net savings for Medicare and 
Medicaid of $426 billion dollars over ten years (Figure 11).       
 
In February of 2010, President Obama proposed his own bill bridging both the 
House and Senate’s bill. This increased the pressure on the U.S. House of 
Representatives to pass health care reform legislation, which they did by amending the 
Patient Protection and Affordable Care Act with Health Care and Education 
Reconciliation Act of 2010 (Healthcare Reform, 2011). President Obama signed the final 
version of the Patient Protection and Affordable Care Act (PPACA) on March 23, 2010 
(GovTrack, 2013).   
 
Proponents and Opponents of the Legislation 
 
 The simplest way to describe the political division created by PPACA, is 
Democrats are for healthcare reform and the Republicans are against it. Reviewing the 
U.S. Senate and U.S. House of Representatives vote record for both the Patient Protection 
and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, 
where no Republican Representatives or Senators voted in favor of either bill, it is clear 
that the Republican Party opposes health care reform and the Democratic Party supports 
it (GovTrack, 2013). Health care reform strikes at the core ideologies of both parties. For 
the Republicans, health care reform represents the expansion of government, increased 
taxation, and negative financial impact to businesses. For the Democrats, health care 
reform provides the expansion of health insurance to millions of uninsured citizens 
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creating greater access to medical treatment, increases the cost sharing for medical 
treatment with the industries that are directly benefiting from the high cost of health care 
in the United States, and introduces the model of fee for value versus fee for services by 
associating reimbursements with the quality of care received. Opposition to PPACA 
resulted in the U.S. House of Representatives approving The Repealing the Job-Killing 
Health Care Law Act in January of 2011 after the Republican Party regained the 
majority. The Repealing the Job-Killing Health Care Law Act was subsequently rejected 
by the U.S. Senate in a 51-47 party-line vote (Healthcare Reform, 2011). 
 
 In addition to the attempted repeal of PPACA, opponents also argued that 
Congress did not have the authority to enact the individual mandate that all citizens are 
required to participate in health coverage or be subject to a fine. Opponents point to the 
lack of provision(s) within the U.S. Constitution guaranteeing a right to health care 
services provided by the government to those who cannot afford it. Proponents argue that 
based on the Commerce Clause and the Necessary and Proper Clause, Congress does 
have the authority to enact such laws (Burgess, 2013). The Commerce Clause gives 
Congress the authority “to regulate commerce with foreign nations, and among the 
several states, and with the Indian tribes” (Commerce Clause, 2013) and the Necessary 
and Proper Clause states that Congress has the power “to make all laws which shall be 
necessary and proper for carrying into Execution the foregoing Powers, and all other 
Powers vested by this Constitution in the Government of the United States, or any 
Department or Officer thereof.” (Necessary and Proper Clause, 2013) Six challenges to 
PPACA were submitted to the U.S. District Courts, of which the Sixth Circuit Court of 
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Appeals in Cincinnati, OH upheld the entirety of PPACA but the Eleventh Circuit Court 
of Appeals in Atlanta, GA found the individual mandate to be unconstitutional (Burgess, 
2013). In response to the Eleventh Circuit Court’s ruling, the Supreme Court was 
petitioned by the Justice Department to decide the constitutionality of the individual 
mandate within PPACA.  The Supreme Court heard arguments, for and against, the 
constitutionality of the individual mandate and on June 28, 2012 Justice John Roberts 
summarized the ruling in his concluding opinion as follows: 
 
“The Affordable Care Act is constitutional in part and unconstitutional in 
part. The individual mandate cannot be upheld as an exercise of 
Congress’s power under the Commerce Clause. The Clause authorizes 
Congress to regulate interstate commerce, not to order individuals to 
engage in it. In this case, however, it is reasonable to construe what 
Congress has done as increasing taxes on those who have a certain amount 
of income, but choose to go without health insurance. Such legislation is 
within Congress’s power to tax.” (Roberts, 2012) 
  
Due to the lack severability in PPACA, if any component of the act is found 
unconstitutional the act in its entirety is at risk. The Supreme Court ruling addressed the 
constitutionality of the individual mandate based on the Commerce Clause but the ruling 
did not eliminate the potential for further litigation. As part of this ruling, the Supreme 
Court also ruled that state participation in Medicaid expansion is optional and that states 
choosing to not participate cannot be penalized (Roberts, 2012).  
 
 At the state level, many Governors refused to accept the Medicaid expansion 
funds offered under PPACA. The Medicaid expansion program was effective January 
2014 providing increased medical access to the poorest Americans by broadening 
Medicaid eligibility to individuals less than sixty-five years of age with income below 
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133% of the federal poverty level. The financial impact to individual states will begin in 
year four of the program when the 100% federal funding shifts to a shared funding model 
ultimately resulting in PPACA receiving 90% federal and 10% state funding in the year 
2020. The expansion of Medicaid creates greater access for the uninsured but increases 
the federal and state financial burden to provide funding for treatment reimbursements. 
South Carolina would add an estimated 500,000 individuals to Medicaid by opting into 
the expansion, but the cost of covering 10% of the program is estimated to reach $1.7 
billion dollars by the year 2020 (The State Paper, 2013). Proponents of expanding 
Medicaid in South Carolina estimate that the total economic output of opting in would be 
$3.3 million dollars and support nearly 44,000 jobs (SCHA, 2012). The expansion of 
Medicaid is a critical debate among health care providers who are concerned about the 
increasing demand to provide quality health care for uninsured/underinsured individuals 
while maintaining financial viability. Hospitals across the state are addressing the 
pending reduction in reimbursements as the industry shifts from fee for service to fee for 




It is estimated that without the implementation of health care reform legislation, 
the combined expense of Medicare, Medicaid and Social Security would exceed the 
projected tax revenue of 18.2% in approximately 2050 (Hartung, 2012). As noted in 
Figure 4, the payer mix from the period of 1999-2011 has seen a 9% decrease in 
employer sponsored insurance and a 10.10% increase in government insurance and the 
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uninsured, combined.  This trend demonstrates that employer sponsored health insurance 
is declining and individuals are either receiving health care through government 
insurance programs or are foregoing health insurance. The impact of an increasing 
uninsured population translates to individuals being limited in their health care spending. 
This limitation results in a percentage of the population that only obtains episodic care 
when it is absolutely necessary, avoiding the expense of preventive care.     
 




Notes: Data is for the entire US population. Percentages do not add up to 100% because some people 
have more than one type of coverage. In 2010, the Census Bureau updated its coverage data for current 
and prior years to reflect changes in the methods used to impute health insurance for non-respondents. 
Government insurance includes military coverage. (U.S. Census Bureau, 2011) 
 
 PPACA addresses the trends described above by establishing the requirement that 
U.S. citizens and legal residents must have health insurance. This is accomplished by 
requiring states to establish state-based health insurance exchanges that provide cost 
effective purchasing options for individuals and small businesses to reduce the financial 
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burden associated with paying health insurance premiums. For those individuals and 
employers that choose not to participate in the insurance exchanges, individual and 
employer mandates to maintain health insurance will be instituted as part of PPACA. The 
individual mandate will require U.S. citizens and legal residents to have qualifying health 
coverage or pay a maximum annual tax penalty of $2,085 or 2.5% of household income. 
The tax penalty will be phased in over a three-year period starting in 2014. After 2016, 
the penalty will increase based on the cost-of-living adjustment (Kaiser Family 
Foundation, 2011). Employers with fifty or more full-time employees that do not offer 
health insurance will be assessed a fee of $2,000 per employee and employers with more 
than two hundred employees will be required to automatically enroll employees into 
company provided health plans (Kaiser Family Foundation, 2011). Small businesses with 
less than twenty-five employees and average annual wages less than $50,000 will receive 
a tax credit for purchasing employee health insurance. Individuals with incomes up to 
133% of federal poverty level will be eligible for Medicaid coverage under PPACA 
Medicaid expansion provision. This will insure that individuals that are not able to 
purchase insurance through the state health insurance exchanges will be eligible to 
receive essential health benefits. As stated previously, Medicaid expansion will be 
federally funded for the first three years, transitioning to a 90% federal / 10% state 
supported program by the year 2020. 
 
 PPACA improves affordability of medication for seniors by reducing the gap 
known as the “donut hole” in Medicare Part D. As a result of the changes to Medicare 
part D people in the “donut hole” received a 50% discount on covered brand name drugs 
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and 14% discount on generic drugs in 2012. The financial gain of this improvement 
translates to a $5.7 million dollar savings on prescription drugs over the past two years 
(Healthcare.Gov, 2013). In addition to improving the affordability of medications, 
PPACA requires insurance plans to eliminate cost sharing (deductibles and co-pays) for a 
variety of preventive health services. In 2011 and 2012, 71 million Americans that were 
enrolled in private health insurance obtained preventive health services without cost 




 To accommodate the increase in patient volumes due to greater access to medical 
care, PPACA addresses the workforce impact by providing the following provisions: (1) 
through the establishment of a multi-stakeholder Workforce Advisory Committee, 
develop a national workforce strategy; (2) redistribute unused General Medical Education 
(GME) slots to states with the lowest resident physician-to-population ratios, with 
primary care and general surgery being prioritized; (3) increase the number of Teaching 
Health Centers, defined as community-based, ambulatory patient care centers that are 
reimbursed under the same guidelines as primary care residency programs; (4) expand 
health professional workforce supply and support training via scholarships and loans 
providing specific focus to preventive medicine, public health, and interdisciplinary 
mental and behavioral health training; (5) prepare for the projected shortage of nurses by 
increasing the availability of nursing education programs, providing loan repayment 
assistance, and establishing a career ladder to nursing. Increase grant opportunities to 
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train family nurse practitioners that are willing provide care in federally qualified health 
centers and nurse-managed clinics; and (6) increase the support for the development of 
primary care training models that focus on medical homes, coordinated management of 
chronic disease, and programs that address both physical and mental health (Kaiser 
Family Foundation, 2011).  
 
The National Health Services Corps is a great example of how workforce 
provisions of PPACA are making a difference. The National Health Service Corps is a 
federal government program that is part of the Department of Health and Human 
Services. Due to the investments from PPACA, nearly 10,000 Corps clinicians are 
providing care to more than 10.4 million people located in rural, urban and frontier 
communities (Healthcare.Gov, 2013). The expansion of the National Health Service 
Corps is in direct response to increased federal funding to repay educational loans and 
provide scholarships to clinicians that practice in areas of the country that do not have 
enough medical professionals to serve the people who live there. Specifically, The 
National Health Service Corps will receive $1.5 billion dollars over a five-year period, 
starting in 2011, in support of continued expansion into medically underserved areas 
(Kaiser Family Foundation, 2011).    
 
Information Technology is a focal point of delivery under PPACA through the 
establishment of ACO’s. Elliot S. Fisher first described the term ACO in 2007 as “the 
United States Health Care System suffers from serious gaps in quality and widespread 
waste stimulating a broad array of public - and private - sector initiatives to improve 
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performance. These include not only public reporting, pay-for-performance (P4P), and 
quality improvement programs but also major initiatives by the organizations responsible 
for institutional accreditation and professional certification” (Fisher, 2007). Under the 
guidance of The Centers for Medicare and Medicaid Services (CMS), health 
organizations can utilize electronic medical record solutions that are meaningful in use to 
exchange patient data and coordinate care. The coordination in care is meant to establish 
specific cost saving benefits through the reduction of duplication in services and establish 
a preventive health care model to replace the current reactionary model (Hartung, 2012). 
The specifics of the CMS proposal for ACO’s is: (1) have a minimum of 5000 patients, 
all participants must have a medical home; (2) meet a minimum standard with respect to 
65 quality measures before being eligible to receive bonus payments; (3) produce 
minimum savings targets based on the quantity of patients participating; (4) establish and 
maintain a governing body that consists of 75% ACO participants with at least one 
patient participating on the governing board; (5) cannot exclude at risk patients from 
participating; and (6) must retain at least 25% of bonus payments as escrow for future 




The need for a national quality improvement strategy is identified as part of 
PPACA and prioritizes the improvement of delivering health care services, patient health 
outcomes, and population health (Kaiser Family Foundation, 2011). PPACA prioritizes 
the improvement of overall health in an effort to reduce the expense of providing care. By 
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addressing the quality of care and gradually transforming the health care industry to a 
more preventive care model, patient outcomes will improve. The focus on quality is 
apparent by the increased value placed on reimbursement based on core measures of 
quality and the objectives of the stages of “Meaningful Use” identified as part of the 
HITECH Act.  
 
The establishment of preventive care under PPACA is supported by the 
following: (1) eliminate preventive service cost-sharing under Medicare to promote 
access to essential preventive health screenings; (2) states that provide Medicaid 
coverage for preventive services can eliminate cost-sharing; (3) establish an annual 
comprehensive health risk assessment for Medicare participants; (4) provide behavior 
modification incentives for both Medicare and Medicaid enrollees; and (5) require 
qualified health plans to eliminate cost sharing for preventive services such as 
recommended immunizations, preventive care for infants and adolescents, and preventive 
care for women (Kaiser Family Foundation, 2011). In addition to offering preventive care 
measures, PPACA penalizes hospitals by reducing Medicare reimbursements for 
preventable hospital readmissions and hospital-acquired conditions. Both preventive care 
and the reduction of preventable hospital admissions require improved management of 
chronic diseases. Without chronic disease management a very small percentage of 
individuals within any health plan incur the majority of the expense. Through chronic 





Accountable Care Organizations 
 
 Centers for Medicare and Medicaid Services define ACOs as “groups of doctors, 
hospitals, and other health care providers, who come together voluntarily to give 
coordinated care to their Medicare patients. The goal of coordinated care is to ensure that 
patients, especially the chronically ill, get the right care at the right time, while avoiding 
unnecessary duplication of services and preventing medical errors.” (CMS, 2015). The 
incentive for health care providers and organizations to participate is the potential of 
increased reimbursement by sharing any savings associated with the reduction in patient 
care expense. 
 
ACOs take the pay-for-performance model beyond the health care provider and 
introduce the idea of significantly reducing the overall expense of health care by 
integrating into the workplace, home and communities (McLellan, 2012). “It envisions 
the medical home as a central locus in a spectrum of health care services applying 
evidence-based approaches in joint ventures among organizations that decrease the 
fragmentation of the current system” (McLellan, 2012). Elements of an ACO are: (1) 
Care teams composed of primary care physicians, physician assistants, nurse 
practitioners, specialists, and others who coordinate patient care, (2) added focus on 
evidence based medicine, quality outcomes and safety, (3) increased use of information 
technology and (4) reduction of high-volume and high-profit margin services with a new 




While the origination of ACOs is linked to Medicare patients, it is not specifically 
a Medicare only initiative. The following section will describe the tools utilized in ACOs 
to evaluate overall health of participants and the coordination of care, how the ACO 
model is related to this project, and how the utilization of the ACO model differentiates 
this project from other wellness programs described previously. 
 
Accountable Care Organization Tools 
 
 The premise of an ACO is that if the right patient care is delivered at the right 
time, expense will decrease and outcome quality will improve. To accomplish this, 
ACO’s utilize patient risk modeling tools to identify high-risk patients, both current and 
potential, and provider coordination tools to assist in coordinating and tracking the care 
received to manage chronic illnesses. 
 
 Risk modeling is accomplished by using a variety of commercially available 
software tools. These tools utilize proprietary algorithms that assess health services 
claims data to determine the risk associated with a given patient and identify health care 
trends that may indicate specific disease maintenance. The claims data is collected using 
a specific submission file type, Health Claim Transaction Set (837) that was established 
as part of the HIPAA Act of 1996. The 837 transaction set includes the following items 
for a single care encounter between patient and provider: (1) a description of the patient, 
(2) the patient’s condition for which treatment was provided, (3) the services provided, 
and (4) the cost of the treatment (1EDISCOURCE, 2015).  The detailed specification for 
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the content and the uses of an 837 file is, “The X12 Transaction contains the format and 
establishes the data contents of the Health Care Claim Transaction Set (837) for use 
within the context of an Electronic Data Interchange (EDI) environment. This transaction 
set can be used to submit health care claim billing information, encounter information, or 
both, from providers of health care services to payers, either directly or via intermediary 
billers and claims clearinghouses. It can also be used to transmit health care claims and 
billing payment information between payers with different payment responsibilities 
where coordination of benefits is required or between payers and regulatory agencies to 
monitor the rendering, billing, and/or payment of health care services within a specific 
health care/insurance industry segment. For purposes of this standard, providers of health 
care products or services may include entities such as physicians, hospitals and other 
medical facilities or suppliers, dentists, and pharmacies, and entities providing medical 
information to meet regulatory requirements. The payer refers to a third party entity that 
pays claims or administers the insurance product or benefit or both. For example, a payer 
may be an insurance company, health maintenance organization (HMO), preferred 
provider organization (PPO), government agency (Medicare, Medicaid, Civilian Health 
and Medical Program of the Uniformed Services (CHAMPUS), etc.) or an entity such as 
a third party administrator (TPA) or third party organization (TPO) that may be 
contracted by one of those groups. A regulatory agency is an entity responsible, by law or 
rule, for administering and monitoring a statutory benefits program or a specific health 
care/insurance industry segment.” (ASCX12, 2015) In addition to utilizing EDI 837 files, 
adjudicated claims from individual payers also provide an indication of the types and cost 
of care being received. Adjudicated claims are the finalized reconciliation of service and 
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payments that are agreed upon by the provider and the payer. This information is specific 
to items that occurred in the past so it is not appropriate for assessing current health 
issues but provides a significant retrospective view by payer. By collecting this 
information, it is possible to evaluate both the care and the cost associated with medical 
treatment and assign a risk score for the individual patient, accordingly. Those 
individuals scoring higher in a risk scale can then be evaluated to determine if the score is 
related to specific episodic care, chronic disease management, or excessive use of health 
care services.  
 
 Utilizing the risk modeling tools identifies individuals that may benefit from 
additional care planning or care management. Physicians and care managers utilize 
information system care coordination tools that require additional clinical information to 
be available to provide a complete picture of the care each patient is receiving. The 
challenge with these systems is the ability to collect all care information and provide a 
complete clinical picture. To overcome this challenge, most care coordination tools are in 
the form of an electronic dashboard that consolidates multiple sources of clinical 
information into a single view. This allows physicians and care managers to evaluate care 
received over a period of time as well as dive deeper into the details of any given episode. 
Collecting all clinical information is achieved through a health information exchange 
solution that receives clinical data via information system interfaces from electronic 
health record systems. Conceptually, collecting clinical data and consolidating the 
information into a single view is simplistic, but when considering the number of 
physicians, clinics, and hospitals that may be utilized by an individual increases the 
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complexity exponentially. The benefit of collecting the clinical information into an 
electronic dashboard allows providers to evaluate prior clinical information collected by 
other providers to potentially reduce duplication in services as well as create a source for 
care coordination and patient compliance tracking. This can be demonstrated when a 
primary care provider has the ability to review current medications, laboratory results, 
and possibly condition monitoring by the patient.  
 
Accountable Care Organizations and This Project 
 
 The focus of this project is to evaluate the return on investment for individuals 
that are participating in a workplace wellness program to improve both the cost and 
quality of life associated with diabetes disease management. The accountable care tools 
described previously are utilized in this process by first assigning a risk score for 
individuals of a specific population within an organization via a commercially available 
ACO risk management tool. Once the individuals with high-risk scores are identified, 
care coordination in the form of case managers can be established to assist with specific 
disease management. The ACO model provides broader visibility to individual’s health 
care utilization, which allows for a more holistic approach to care management. 
Establishing the risk score using ACO tools prior to implementing care coordination also 
provides the ability to track individual participant’s progress over a period of time versus 
tracking disease specific diagnostic scores. Specifically, utilizing ongoing risk score 
evaluations based on adjudicated claims or 837 files will provide insight into health care 
visits, medication expenses, and laboratory results versus traditional diabetes disease 
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management that consists of regular monitoring of glucose or A1C levels.      
  
Difference from Other Diabetes Wellness Programs 
 
 Previous research utilizing PepsiCo’s HealthRoads workplace wellness program, 
assesses the financial impact of workplace wellness programs, specifically diabetes, by 
evaluating claims data and providing a self-administered health risk assessment (Liu, et 
al., 2013). Based on the results of the evaluation and health risk assessment, individuals 
were eligible for case management, disease management, lifestyle management, and a 
nurse advice line. The program did not utilize commercially available ACO tools to 
assess the claims data or evaluate overall success of the program. The research completed 
by Liu et al. (2013) only evaluated the benefit side of a cost-benefit equation and was 
unable to estimate the return on investment due to not having access to the related 
program costs.  
 
Additional workplace wellness programs discussed previously, identify the top 
four categories of health quality improvements as, increased exercise level, health risk 
reduction, smoking cessation, and decreased blood pressure (Kaspin, Gorman, and 
Miller, 2013). Diabetes disease management is a relatively new focus area of workplace 
wellness programs that requires a higher level of participant support systems to improve 
the management of the disease. The coordinated care team, provided to participants as a 
support system, is focused on improving the access to care as well as reducing the cost of 
care to manage a healthy lifestyle which is a commonality between ACO’s and 
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workplace wellness programs. Utilizing an ACO model within a specified workplace 
with access to the program costs information and clinical data will provide better insight 
into the return on investment associated with a workplace wellness program focused on 


























 The population of this study to answer the research question, “Can using an ACO 
commercially available software tool and a diabetes wellness workplace management 
program be combined to identify 1 year ROI in a sample of patients within an average 
size institution?” is a subset of individuals that receive health benefits from a self-insured 
employer at a reduced insurance premium. To participate in the reduced insurance 
premium plan, individuals that have at least one or any combination of the following 
physiological indicators: a BMI greater than or equal to 50, a glucose of greater than or 
equal 200 mg/dL, an A1C equal to or greater than 7.0, and a risk score as calculated by 
the CCMS commercial ACO software must comply with a workplace wellness program. 
The workplace wellness program is provided by the employer in an effort to improve the 
management of workforce health and assist employees that need focused care 
management for diabetes. Focused care management is accomplished by assigning health 




In an attempt to answer the proposed research question, de-identified data 
obtained will be evaluated using the outcome evaluation model. The outcome evaluation 
model, which is also known as an impact assessment, “focuses on the accomplishments 
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and impact of the service program, or policy and its effectiveness in attaining the 
intended results that were set prior to program or policy implementation” (Shi, 2008).  It 
allows for an evaluation of an enhanced or modified program compared to standard 
program methods. The outcome evaluation model allows the program to be evaluated 
based on the benefits of the intervention to determine if the program changes are an 
improvement of the program. Specifically, outcome evaluations are interested in 
answering the following questions: (1) What are the goals and objectives of the 
program?, (2) How are they measured and assessed?, (3) What alternative programs are 
available to this program?, (4) How are the essential components of the program related 
to achieving goals and objectives?, (5) How successful is the program in accomplishing 
intended results?, (6) How effective is the program?, (7) How costly is the program?, (8) 
Which program components best accomplish goals?, (9) What gaps exist in meeting the 
goals?, (10) What changes should be made to improve the efficiency of meeting program 
goals?, (11) What are the positive and negative unanticipated outcomes of the program?, 
and (12) What decisions can be made regarding the program continuation or expansion? 
(Shi, 2008). Outcomes research performed at the patient level is generally focused on the 
most prevalent, costly, medical conditions that have alternative clinical strategies. This 
type of research involves linking the care received by a variety of patients with a 
particular condition to positive and negative outcomes in order to determine what 
interventions work best for patients (Guadagnoli and McNeil, 1994).  
 
The purpose of the evaluation described in more detail later in this Methods 
section, is to compare retrospective cost data of providing health care for diabetics in the 
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study, prior to and after twelve months of participating in the program, in an effort to 
calculate the return on investment utilizing a diabetic ACO model. In addition to 
determining the return on investment, using the outcome evaluation model will also 
provide insight into the strengths and weaknesses of the program as well whether to 
continue the program as originally implemented.   
 
It has also been noted that outcome research is concerned with the “movement to 
managed care and the organization of previously independent health care providers into 
integrated networks” (Shi, 2008) which can range from the older model of managed care 
solutions into the most recently proposed ACO model. As mentioned previously, a key 
goal of the ACO model is to change the health care reimbursement model from a fee for 
service model to a pay for performance reimbursement model focused on the reduction of 
overall individual health care expenses via proactive health and/or disease management. 
To elicit the adoption of this new reimbursement model by providers requires this 
assessment to determine if the additional expenses associated with providing care 
management results in a positive return of investment.   
 
The actual evaluation of the data will be performed as a repeated measures 
longitudinal study (Shi, 2008), which will allow for a review of program participants 
A1C values over a twelve-month period during the time frame of October 2013 to 
September 2014. The data collected from the individual participant will be used to trend 
the impact of care management on each individual participant’s A1C for those identified 
with a BMI greater than or equal to 50, a glucose of greater than or equal 200 mg/dL, and 
62 
 
an A1C equal to or greater than 7.0, during an annual work place wellness health 
assessment. The longitudinal trend analysis will be based on the prior year health care 
cost compared to the health care and program cost for the twelve-month program period 
for each participant. The data will be an A1C score recorded, at least quarterly, for each 
participant and trended for a twelve-month period. This information will be matched to 
the specific care management interventions that were provided during the same period. 
Based on both sets of data, an additional ACO risk score will be calculated at the end of 
the evaluation period to determine if the program expenses incurred per participant 
results in an improvement in the overall, prior to program participation, medical care 
costs associated with the treatment of diabetes. The ACO risk score is calculated using a 
commercially provided software tool with proprietary algorithms that assess health 
services claims data to determine the risk associated with a given patient and identify 
health care trends that may indicate specific disease maintenance. The claims data is 
collected using a specific submission file type, Health Claim Transaction Set (837) that 
includes the following items for a single care encounter between patient and provider: (1) 
a description of the patient, (2) the patient’s condition for which treatment was provided, 
(3) the services provided, and (4) the cost of the treatment (1EDISCOURCE, 2015). Due 
to the proprietary nature of the algorithm used to calculate the risk score, it is difficult to 
know all the factors, other than the 837 file, used to calculate the participant risk score. It 
is assumed that participant age and corresponding diagnoses have an impact as well. This 
design is best suited to answer the research question as it allows for the evaluation of the 
pre and post program health care costs for diabetic patients that participate in a workplace 





 Self Regional Healthcare, in partnership with McKesson, is an ACO 
demonstration site. As a demonstration site, Self Regional Healthcare has decided to 
validate the ACO model by enrolling all current team members in McKesson’s 
Coordinated Care Management System (CCMS), which is a workflow tool that enables 
payers to focus resources, better coordinate care through automation and effective 
communication, integrate data at key points in the workflow, and base interventions on 
evidence-based standards of care (McKesson, 2012). The CCMS solution collects 
insurance claim data from insurance companies via technical interfaces, matching patient 
claims and assessing the current patient diagnosis. It does this in an effort to provide 
patient populations that are in need of specific health interventions to obtain improved 
health through appropriate care management. Through the CCMS tool, individuals 
receive a risk score based on their specific insurance claims information reported in an 
industry standard 837 insurance claims file. Individuals that receive a high-risk score are 
assigned a health coach that facilitates a specific care plan based on the specified 
categorizations of obesity, hypertension, and diabetes. The health coach is responsible for 
providing education to each participant that explains the program benefits. During the 
initial meeting, each participant is interviewed by the health coach. The health coach 
assesses current limitations of access to appropriate health care or lifestyle challenges for 
each participant and offers solutions or guidance to obtain better health. The interventions 
provided by the health coach range from providing access to a primary care provider and 
medication assistance to gym membership and appropriate footwear to facilitate a more 
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active lifestyle. The health coach maintains regular contact with each participant, 
monthly if possible but quarterly at a minimum, to assess each individual participant’s 
progress and compliance with improving diabetes management and overall health.   
 
 In addition to analyzing Self Regional Healthcare team member’s 837 insurance 
claims file using McKesson’s CCMS tool, each team member covered under the 
corporate health insurance plan is required to complete a health risk assessment that 
includes the collection of key health indicators such as: weight, blood pressure, body 
mass index (BMI), lipid panel, and A1C. Individuals that have a BMI greater than or 
equal to 50, a glucose of greater than or equal 200 mg/dL, or an A1C equal to or greater 
than 7.0 are also provided a health coach to assist in disease management specific to 
diabetes. Having values greater than those required to participate in the program does not 
always correlate with a high-risk score. For this reason participants of the study may not 
have both a high-risk score and correlating physiological values. 
 
 To be included as a participant in the research, the Self Regional team member 
needs to be enrolled in the program for at least twelve months and have any of the four 
following indicators; a BMI greater than or equal to 50, a glucose of greater than or equal 
200 mg/dL, an A1C equal to or greater than 7.0, and a risk score as calculated by the 
CCMS commercial ACO software. The program was initiated in 2013 and enrolled team 
members in the first year it was established as well as during the second year in 2014. 
Table 6 lists the specific research measures that will be collected for each participant 
during the research period. 
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Table 6: Research Measures for Each Participant 
Measures Scales 
Participant characteristics Age, sex, and race 
Length of time in the program for each 
participant Reported in months 
Initial results of health risk assessment for each 
participant Reported as a numeric value 
Initial risk score as determined by commercial 
ACO software Reported as a numeric value 
Risk score as determined by commercial ACO 
software after 12 month participation in the 
workplace wellness program 
Reported as a numeric value 
Weight loss while participating in the program Reported in pounds 
Physical activity while participating in the 
program 
Number a daily steps or physical 
activity as reported by the 
Walkingspree program  
Annual health care cost for each participant 
while participating in the program 
Dollar amount for health care provided 
as reported in the participant’s 837 file 
Total cost of ownership for the ACO software 
Dollar amount of McKesson CCMS 
product. Initial capital cost plus the 
maintenance cost for the program 
period 
Full time equivalents associated with the care 
management staff of the program 
Compensation, including benefits, for 
each full time equivalent health coach 
and program manager 
Health insurance premium reduction for each 
participant (incentive) 
Dollar amount of reduced monthly 
health insurance premium as a result 
for participating in the program 
Program expense for each participant 
Dollar amount of the combined costs 
for the following items if provided to 
each participant: gym membership, 
exercise shoes, reduced meal plan, and 








 The data for this research is based on information collected from participant 
records and health claims information, pre- and post-research time frame, as well clinical 
information collected by the care managers during the research period. The data collected 
is: health specific information (A1C and weight), intervention data (physical activity), 
and health care costs (emergent, inpatient, and ambulatory care) as reported for payment 
via 837 insurance files. In addition to the participant specific health, intervention, and 
claims data, the associated risk score as determined by the CCMS product, is collected 
for each participant at the beginning and the end of the twelve month research period. As 
submitted and approved by the IRB committees at Self Regional Healthcare and the 
Medical University of South Carolina, the data is de-identified by the program 
administrator prior to being analyzed. 
 
 During the study period, the health coach meets with each participant on a regular 
basis, but no more than monthly, to collect program specific health data and assess if any 
additional program interventions are needed. The care managers use a basic spreadsheet 
tool to collect data during each of the interviews with the program participants. The data 




 Due to the lack of a control group associated with the specific research, data will 
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be evaluated using a before-and-after time-series comparison. Specifically, “pre-program 
and post-program outcome measurements are compared to see if the differences are 
significant.” (Shi, 2008). The main focus of the data analysis for this research will be 
determining if the health care cost for each participant during the twelve months, October 
2013 to September 2014, leading up to initiating the program is reduced as a result of the 
program interventions and if the post-program health care expense in addition to the 
program expense provides a positive return on investment. In addition to evaluating the 
return on investment, descriptive data, specifically minimum, median or mean, and 
maximum of each measure, will be determined to provide a detailed understand of the 
study data. To determine if there is a significant difference in individual participant 
medical cost pre- and post- intervention, a two-tailed T-test will be completed (Shi, 
2008).   
  
The tool utilized to evaluate the return on investment of the diabetes wellness 
management program is a cost benefit analysis (CBA) which allows for the benefits and 
the costs of the program to be quantified and translated into a common monetary unit. 
Using the cost benefit analysis as the evaluation tool assists in the decision making 
process for the planning, implementation, continuation, and expansion of health service 
programs (Shi, 2008).  
 
The cost benefit analysis will be assessed by determining: the total health care 
cost for the program participants prior to program initiation (Y0); the health care cost for 
the program participants during the program period (Y1); and the total cost of the 
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program including software expense (Ps), program personnel (Pp), and program 
incentives (Pi). Using these factors, the following formula will be used to calculate the 
program cost benefit analysis which will be used to answer the research question 
proposed previously: 
 
CBA = Y0 – (Y1+Ps+Pp+Pi) 
 
Using this formula, it will be possible to determine if the cost of implementing the 
diabetes workplace wellness program combined with the reduced health care costs of all 
the participants is less expensive than the health care cost of the participants prior to 
initiating the program. If the CBA is a positive number than the program reduced the 
expense of managing the participant population.  
 
While the CBA formula evaluates the cost of implementing the diabetes 
workplace wellness program, it does not account for calculating the actual return on 
investment of the program for the study period. To determine the ROI of the diabetes 
wellness program the ROI formula below was used. 
 
 
Return on Investment = (Investment Gain – Investment Cost) 









Participant Descriptive Data 
 
 The participants included in this project are part of a diabetes workplace wellness 
program at Self Regional Healthcare, Self Cares. Self Cares is an incentive based 
workplace wellness program to maintain healthy habits in return for reduced health 
insurance premium. As part of the program, any individual identified having at least one 
of the following physiological measures as reported during Self Regional Healthcare’s 
annual health assessment: a BMI greater than or equal to 50, a glucose of greater than or 
equal 200 mg/dL, an A1C equal to or greater than 7.0, and a risk score as calculated by 
the CCMS commercial ACO software, were required to participate in a focused diabetes 
workplace wellness program that included health coaches to assist with eliminating 
barriers to improved health behaviors.  
 
From the original group of Self Cares participants, fifty individuals qualified for 
the focused diabetes workplace wellness program. Of the fifty individuals identified, 
twenty-eight participated in the program for at least the first twelve months from October 
2013 to September 2014 and had pre-program data and post-program data. The data 
points required for the analysis where: weight, A1C, health care and medication expense, 
CCMS risk score, diabetes workplace wellness program expense. The demographics for 
the twenty-eight participants were: 54% (n=15) Caucasian, non-Hispanic, 46% (n=13) 
African American, 29% (n=8) male, and 71% (n=20) female. The age of the twenty-eight 
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participants ranged from the youngest being twenty-five years old and the oldest being 
sixty-four years old at the beginning of the program. The median age of the participant 
group was forty-nine years old. The largest grouping of the participants was from forty to 
fifty-nine years old as shown in Table 7.    
 
Table 7: Summary of Program Participant Data 
Age Group (years of age) Program Participants 
by Age Group 
Percentage by Age Group 
25 – 29  3 10.71% 
30 – 34  3 7.14% 
35 – 39  3 7.14% 
40 – 44  4 14.29% 
45 – 49 4 14.29% 
50 – 54 5 17.86% 
55 - 59 6 21.43% 
60 - 64 2 7.14% 
N = 28 100% 
Minimum 25 years of age  
Median 49 years of age  
Maximum 64 years of age  
 
 
 The annual health assessment that all Self Regional Healthcare employees are 
required to complete collects: weight, blood pressure, BMI, glucose, cholesterol, 
LDL/HDL, triglycerides, and A1C. Table 8 provides a summary of the initial health 
assessment data for the twenty-eight participants in the diabetes workplace wellness 
program. The minimum, median, and maximum values are calculated based on the 












Chol LDL/HDL Trig A1C 
Minimum 174 115/55 25 80 99 29/17 53 5.9 
Median 253 143/76 41 191 166 96/39 107 8.15 
Maximum 388 176/100 58 328 419 145/77 3456 14.5 
  
 
When reviewing the raw data, it is interesting that the participant with the lowest 
weight (174 lbs.) also has the lowest BMI (25) but has an A1C of 8.0 which is very close 
to the median (8.1) for the group. This participant’s glucose is reported as 142 mg/dL 
which is below the recommend diabetic threshold of 200mg/dL. This participant’s data 
validates the need to evaluate multiple physiological indicators versus a single indicator 
when assessing an individual’s ability to process glucose. The reported data for this 
individual is also an example of how A1C and fasting glucose screenings can contra 
indicate each other as previously discussed. A fasting glucose of 200mg/dL or greater and 
an A1C of 7.0 or greater results in a diagnosis of diabetes. This participant has a glucose 
of 142mg/dL, well below the established diabetic threshold, and an A1C of 8.0 which is 
above the diabetic threshold of 7.0.  
 
Program Specific Data 
 
 The program specific data collected for the diabetes workplace wellness program 
was pre- and post- program values for weight comparison, recorded step counts as a 
measure of physical activity, A1C scores, risk score as calculated by the CCMS software, 
health care costs as reported by the participants individual 837 file submissions, and 
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pharmaceutical costs as recorded by Self Regional Healthcare’s health insurance 
provider. The purpose of collecting the pre and post program data is to evaluate the 
impact of the diabetes workplace wellness program on the participant’s specific collected 
physiological values. 
 
 Overall, as a group, the twenty-eight participants of the study had a mean weight 
of 269 pounds pre-program and a mean weight of 271 pounds after the first twelve 
months. The difference between pre- and post- program mean weight was an increase of 
a 1.6 pounds, see Table 9. Although there was a mean increase from the beginning of the 
program several participants succeeded in losing weight over the twelve month program. 
Eleven participants lost weight during the program. The weight loss by participant ranged 
from 1.0 pound to the maximum loss of 19 pounds. In contrast, seventeen of the 
participants gained weight during the program. Those participants that gained weight saw 
an increase ranging from 1.0 pound to 25 pounds. One participant was recorded as 
maintaining weight with a weight of 202 pounds during the initial health assessment and 
after twelve program months.  
 









Minimum 174 175 -19 
Mean 269 271 1.6 






 As part of the diabetes workplace wellness program, participants were provided 
pedometers that facilitated physical activity reporting on a quarterly basis over the twelve 
months of the program. Table 10 provides a summary of the results of the quarterly 
tracking of participant step counts as recorded on personal pedometers. The mean step 
count for each quarter was reported as 624,993 steps in the first quarter decreasing to 
491,371 steps in the fourth quarter of the program. Similarly to the decrease in total steps 
per quarter, the mean for the daily step average of the twenty-eight participants was 6,844 
in the first quarter declining to 4,791 in the last three months of the twelve month 
program. Only one participant did not record any steps for the twelve months of the 
program. Three quarters of the program participants (75%) recorded steps for the 
duration of the program.  A point of interest from the data was three of the four quarters 
of maximum steps was completed by the same program participant with the first quarter 
step count for this participant being 15,290 steps less than the maximum reported. 
 



























Minimum 0 0 0 0 0 0 0 0 
Mean 624993 6844 532883 5941 516278 5298 491371 4791 
Maximum 1222178 13285 1369752 15219 1369752 15219 1178633 12952 
 
 
 To evaluate the improvement of diabetes disease management as part of the 
diabetes workplace wellness program, A1C scores were recorded during the initial health 
assessment and used to identify program candidates that had a value equal to or greater 
than 7.0. To evaluate the impact of the program on the blood glucose management for 
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each participant, A1C values were also collected after twelve months of the program. It is 
important to note that not all participants had an A1C equal to or greater than 7.0 but the 
lowest A1C reported at the initiation of the program was 5.9 which close to the A1C 
range (6.0 to 6.5) that is used to qualify an individual as pre-diabetic and at risk for 
developing Type 2 diabetes.  
 
 The pre-program A1C mean for the twenty-eight participants was 8.5 with a 0.7 
mean improvement over the twelve month program (Table 11). The greatest reduction by 
a single participant in A1C over the program period was 5.6, from 14.5 to 8.9. With one 
participant recording an increase in A1C from 6.3 to 8.5.  Overall 64% of participants 
experienced a reduction in A1C during the program period with two participants seeing 
no change. Both of these participants recorded a pre- and post-program A1C of 6.0. Six 
of the participants that recorded an initial A1C equal to or greater than 10.0 had a 
reduction in A1C greater than or equal to 1.0, see Table 16. It is also important to note 
that the pre-program maximum A1C value was 14.5 and the maximum post-program 


















CHP15746290901 6.6 6.3 -0.3 
CHP25178081501 10.2 8.6 -1.6 
CHP21482500701 8.5 7.1 -1.4 
CHP25008433601 6 6 0 
CHP25053503301 9.3 9.5 0.2 
CHP24723330601 6.4 6.8 0.4 
CHP25021709601 11.1 10.1 -1 
CHP25041451701 9 8.7 -0.3 
CHP41664936301 11.1 10.2 -0.9 
CHP24745113901 6 6 0 
CHP24841728501 7.9 8.6 0.7 
CHP24813901301 8.4 8.5 0.1 
CHP25080979301 8.2 7.2 -1 
CHP43169645401 9.7 9 -0.7 
CHP24785613901 6.3 8.5 2.2 
CHP26023799601 6.8 6.6 -0.2 
CHP24943148401 12.1 8.7 -3.4 
CHP24841256101 11.7 10.6 -1.1 
CHP24704060101 6.3 5.7 -0.6 
CHP24911060701 6.2 6.3 0.1 
CHP06460042601 8.1 7.5 -0.6 
CHP25092857801 11.9 11.1 -0.8 
CHP30904538401 7 6.3 -0.7 
CHP13070296401 8 7.6 -0.4 
CHP24781670701 5.9 6 0.1 
CHP25117954601 14.5 8.9 -5.6 
CHP24711478601 10 6.3 -3.7 
CHP24955270901 6.1 6.4 0.3 
Minimum 5.9 5.7 -5.6 
Mean 8.5 7.8 -0.7 
Maximum 14.5 11.1 2.2 
 
 
The risk score data reported as part of the program was determined by using the 
commercially available risk ACO software, CCMS, provided by McKesson. The risk 
score software uses the individual participant’s 837 insurance file and pharmaceutical 
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claims data provided by the organizational health care insurance provider to calculate a 
risk score that is used to rank the individual financial risk associated with an individual’s 
health. While the risk score was not used as an identifier for program participants, it was 
a key data point that needed to be analyzed to determine if the risk score is similar to 
changes in the other program indicators, such as change in weight and A1C values for 
each participant. 
 
The pre-program risk scores for the twenty-eight participants ranged from 0.13 to 
10.91 with a mean of 2.09 (Table 12). The higher the score, the greater the financial risk 
of the individual participant. The post-program risks for the same group were from 0.65 
to 12.25 with a mean of 2.35. As represented by the pre- and post-program mean values, 
risks score for the twenty-eight participants increased over the twelve month program 
period. In fact, only 29% of the program participants were successful in reducing their 
individual risk score. The greatest decrease and increase in the risk score for the twenty-
eight program participants was -3.87 and 3.92, respectively.  
 









Minimum 0.13 0.65 -3.87 
Mean 2.09 2.35 0.26 
Maximum 10.91 12.25 3.92 
 
 
 Participant health care cost, including emergent, inpatient, and ambulatory care, is 
analyzed by calculating the pre-program and post-program difference for all twenty-eight 
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program participants. Total health care cost pre-program is $152,677. Total health care 
cost after the twelve months of the program is $107,915 which resulted in a savings of 
$44,763. It is important to note that the health care cost does not include the 
pharmaceutical cost during the program. Since the health care cost and pharmaceutical 
data was available separately, it was not combined to allow for an independent evaluation 
of the associated cost. The mean health care cost pre-program was $5,453 compared to a 
post-program mean of $3,854 which yields a mean pre- to post-program difference of 
$1,599 (Table 13). The greatest cost savings recorded was $49,739 and the greatest 
increase in health cost was $17,423. Without a detailed medical record chart abstraction, 
it would be difficult to determine the exact cause of the cost savings or increase. Based 
on the research question and the approved use of de-identified data by the IRB 
committee, medical record chart abstraction is outside the scope of this project. Sixteen 
of the twenty-eight participants (57%) did record a cost savings over the twelve months 
of the program. 
 










Cost Difference  
Minimum $41 $228 -$49,739 
Mean $5,453 $3,854 -$1,599 
Maximum $64,300 $28,477 $17,423 
 
 
 Similar to the health care cost analysis, pharmaceutical cost was calculated by 
determining the difference between the pre-program pharmaceutical cost and post-
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program pharmaceutical cost. The data used for this analysis was provided by Self 
Regional Healthcare’s insurance provider as a de-identified annual pharmaceutical cost 
summary by program participant from October of 2012 to September of 2013 (pre-
program) and October 2013 to September of 2014 (post-program), Table 14. Total 
pharmaceutical cost pre-program is $114,753. Total pharmaceutical cost after the twelve 
months of the program is $152,636 which is an increase year over year of $37,883. The 
mean pharmaceutical cost for pre-program and post-program is $4,098 and $5,451, 
respectively. The mean difference between pre- and post-program is an increase $1,353 
which supports the recorded increase for all twenty-eight participants. Evaluating the 
difference in pharmaceutical cost for the twenty-eight participants, 71% recorded an 
increase. Of those that increased, thirteen of the twenty-eight participants had an increase 
of $1,000 or greater in pharmaceutical cost with the greatest increase being $10,369. 
 











Minimum $22 $247 -$4,838 
Mean $4,098 $5,451 $1,353 











 To determine if there is a significant difference in individual A1C, risk score, and 
participant’s weight as a result of the program, a two-tailed T-test was completed by 
comparing the pre- and post-program data. The results of the two-tailed T-test are 
reported in Table 15. Evaluation of the reported results for the A1C data suggests a 
statistical difference based on the P-Value being less than 0.05 and the T-Calculated Two 
Tail Value of 2.58 being greater than the T-Critical Two Tail Value (2.05). The 
difference for the risk score and weight was not determined to be statistically significant. 
The mean difference for A1C, risk score, and weight is -0.7, 0.26, and 1.6 respectively 
with the A1C data being the only data set to demonstrate a reduction in the A1C values 
for the twenty-eight program participants.    
 
















A1C 2.051830516 2.583585604 0.007756048 -1.294372296 -0.148484847 
Risk 
Score 
2.051830516 1.09132171 0.284774636 -0.228206046 0.746777474 
Weight  2.051830516 0.817661404 0.420707917 -2.42580372 5.640089434 
 
  
To evaluate the health care and pharmaceutical cost difference between pre- and 
post-program participant data, the Wilcoxson Signed Rank Test was used. The 
Wilcoxson Signed Rank Test is used to analyze the cost difference since it is a non-
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parametric version of the T-Test. The Wilcoxson Signed Rank Test compares a critical 
value based on sample size and a calculated test value. If the calculated test value is less 
than the critical value, sufficient evidence exists to suggest there is statistical difference 
between the pre- and post-program cost data. The Wilcoxson Signed Rank Test critical 
value for a sample size of twenty-eight is 116. The calculated test value for health care 
cost and pharmaceutical cost is 171 and 78, respectively. This suggest that there is 
statistical difference in the pharmaceutical cost data (78<116) but not the health care cost 
data (171>116).   
 
In addition to determining statistical differences in the A1C, risk score, weight, 
health care cost, and pharmaceutical cost for the diabetes workplace wellness program, 
correlation between the A1C and health care costs was evaluated. Using the Spearman 
Rank Correlation Test to evaluate the correlation between the A1C values and health care 
cost without assuming a linear relationship. Spearman’s Rank Correlation Test compares 
a calculated value based on a 1 to -1 scale, where 1 and -1 implies a correlation of the 
data and 0 implies no correlation. The calculated Spearman Correlation value for the pre- 
and post-program difference for A1C and health care cost is 0.073618 which is closer to 
0 than 1 indicating little to no correlation between: (1) the difference between the A1C 
values pre-program and post-program and (2) the difference in health care cost pre-






Program Cost Data 
 
The cost benefit analysis (Table 16) assesses: the total health care cost for the 
program participants prior to program initiation (Y0); the health care cost for the program 
participants during the program period (Y1); and the total cost of the program including 
software expense (Ps), program personnel (Pp), and program incentives (Pi). Using these 
factors, the following formula was used to calculate the program cost benefit analysis. 
 
CBA = Y0 – (Y1 + Ps + Pp + Pi) 
 
 Pi is the program incentive for the twenty-eight participants. It includes: the 
annual cost of gym memberships for those participants that enrolled as part of the 
program, the total cost of sneaker vouchers provided to those participants that lacked 
appropriate exercise footwear, and the $200 per month per participant reduced health 
insurance premium. Pi for the twenty-eight program participants equals $94,920.00 for 
the twelve months of the program. Pp is the labor expense for the employees that 
administered the program which included the health coach and a .25 portion of a team 
leader. The total program expense for Pp was $117,944.00. Ps is the cost to implement 
the CCMS ACO software that was used to calculate each participants risk score. The total 
cost of Ps was $573,640.64. Y1 is the total health care and pharmaceutical cost recorded 
for each program participant of the twelve month program, equaling $260,550.90. Y0 is 
the same calculation as Y1 accept it is using the pre-program health care and 
pharmaceutical data. Y0 equals $267,429.99. The calculated Cost Benefit of the diabetes 
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workplace wellness program is a - $779,625.55. The resulting negative CBA value 
indicates the diabetes workplace wellness program cost more in the first twelve months 
than the savings associated with health care and pharmaceutical cost. It is important to 
note that the cost difference of health care and pharmaceutical cost pre- and post-program 
was a savings of $6,879.09.  
    
Table 16: Program Cost Benefit Analysis 
 Y0 Y1 Ps Pp Pi 
Gym 
Membership 
    $27,520 
Sneakers     $200 
Reduced Insur. 
Premium 
    $67,200 
1.25 FTE’s    $117,944  
Risk Software   $573,640.64   
Health Care 
Expense 
$152,677.47 $107,914.60    
Pharmaceutical 
Expense 
$114,752.52 $152,635.30    
CBA Total ($779,625.55)     
 
 In addition to calculating the CBA of the diabetes workplace wellness program, a 
return on investment calculation was needed to answer the research question, “Can using 
an ACO commercially available software tool and a diabetes wellness workplace 
management program be combined to identify 1 year ROI in a sample of patients within 
an average size institution?” To determine the ROI of the diabetes wellness program the 
ROI formula below was used.  
 
Return on Investment = (Investment Gain – Investment Cost) 




 The investment gain for the program was the health care and pharmaceutical cost 
savings of $6,879.09, previously discussed. The investment cost is the total cost of Ps, Pp, 
and Pi (Table 21) which equals $786,504.64. Using the calculated investment gain and 
investment cost, the ROI for the diabetes workplace wellness program is –99% as shown 
below.  
ROI = ($6,879.09 - $786,504.64)  
                                                                  $786,504.64 
ROI = - 0.99 
 
 Although the program cost data does not indicate a significant cost savings or 
return on investment for the diabetes workplace wellness program, it is important to 
evaluate all data results of the program before assuming a lack of positive outcome. 
 
 In addition to calculating the ROI based on the savings and expenses associated 
with the twelve month program, a sensitivity analysis was completed on the data 
collected in an effort to understand the impact to ROI. The first sensitivity analysis was 
focused on extrapolating the ROI over a five year period using the data collected as the 
basis of the calculation. Table 16 provides the results of the analysis which is based on: 
an annual growth in participants; expensing the commercial software (Ps) equally over a 
five year period instead of in the first year as above and assuming the software cost is 
static regardless of the number of program participants; increasing the program incentive 
expense (Pi) according to the participant number; and increasing the labor cost (Pp) to 
provide appropriate staffing as the program participants increase. The program savings is 
determined by assuming the expense for each participant will be reduced by $248.68 
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annually. This was calculated by using the total health care and pharmaceutical cost 
savings and dividing it by the number of program participants, twenty-eight, yielding a 
cost savings per participant.  
 
Table 17: ROI Sensitivity Analysis 
 Year 1 Year 2 Year 3 Year 4 Year 5 












Ps $114,728 $114,728 $114,728 $114,728 $114,728 
Pi $339,000 $847,500 $1,695,000 $2,542,500 $3,542,112 
Pp $117,944 $117,944 $235,888 $235,888 $283,066 
Program Savings $24,568 $61,420 $122,841 $184,261 $245,682 
 
 Using the extrapolated data in Table 22 to calculate the ROI over a five year 
period results in the following: 
 
ROI = ($638,773 - $10,378,370)  
                                                                  $10,378,370 
ROI = - 0.94 
 
 Performing a similar analysis but assuming Ps is the only program expense and 
the number of participants increase over a five year period as described in Table 16, 
results in a ROI of 0.11. Using the data collected to create a five year forecast, highlights 








The findings of the evaluation are: (1) The statistically significant difference in 
participant’s A1C values pre- and post-program; (2) The medical and pharmaceutical cost 
difference pre- and post-program; (3) The lack of change in the pre- and post-program for 
both the participant’s weight and ACO risk score; and (4) The negative results of the 
financial evaluation, specifically for the cost based analysis (CBA) and the return on 
investment (ROI).  
 
The improvement in the A1C scores of the study population is the most 
significant finding of the research. As a result of providing a workplace wellness program 
at Self Regional Healthcare, the individuals that participated saw an improvement in the 
management of diabetes as it relates to A1C scores. Through the focused efforts of health 
coaches, the participants not only received assistance with how best to manage their 
diabetes, they understood their current health and how behavior changes could provide 
better overall health. Empowered with this information, the program population began 
this improvement by positively changing their A1C values over the twelve month 
program. Significant evidence exist that demonstrates the more engaged patients are in 
their own care, the better the results are from health interventions or recommended 
behavior changes. The fact that the population of this study saw improvement in their 
A1C scores as a result of the diabetes workplace wellness program is a similar result to 
previous research. The diabetes workplace wellness program provided can be built upon 
by further expanding the program to Self Regional employees that are within the current 
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program range but more importantly individuals that have an A1C 5.5 to 6.0 range, 
considered pre-diabetic, since minimal weight loss and behavior change could prevent 
these individuals from becoming diabetics. Ultimately, that is a policy goal of ACOs 
which is to improve patient’s health and reduce the expense of the health care system by 
having engaged patients that take responsibility for being healthier versus being 
dependent on the health care industry to correct preventable health conditions.    
 
Prior research demonstrates the ability to provide a positive return on investment 
in workplace wellness programs by reducing the overall health care expense per 
employee year over year and/or maintaining or reduce the expense related to provide 
health insurance as an employee benefit. The medical and pharmaceutical cost difference 
from pre- to post-program was the second most significant finding of the research. The 
medical and pharmaceutical costs for the twenty-eight participants was $152,677 and 
$114,753, respectively. The medical and pharmaceutical costs post-program was 
$107,915 and $152,636, respectively. When comparing the combined costs for medical 
and pharmaceutical costs pre- and post-program it was determined that the total cost 
savings was $6,879.09 over the twelve month period. Evaluating the cost data for medical 
and pharmaceutical expenses separately demonstrated that an almost equal cost shift 
occurred. That is, while the medical costs associated with caring for the twenty-eight 
participants decreased, the pharmaceutical costs over the evaluation period increased. 
This is an indication of using medication to better manage diabetes for the twenty-eight 
participants. As discussed previously, patient engagement in their care is a key factor in 
managing a disease like diabetes. Another key component is making sure appropriate 
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health care is accessible. By providing health coaches as part of the program, participants 
were able to receive assistance in obtaining appropriate care in the form of improved 
medication access while reducing episodic treatment by medical professionals. The 
increase in pharmaceutical cost over the twelve month period while medical cost was 
reduced points to engaged participants having access to appropriate disease management. 
Again, tying the diabetes workplace wellness program to the policies of ACOs, 
accessibility to appropriate medical care is included by requiring ACO patients to have a 
medical home and reduce the expense of medical care by focusing more on preventive 
care in place of expensive episodic care. While the diabetes workplace wellness program 
did not eliminate diabetes for the participants, the focused care management did provide a 
more stable management of the disease by reducing the amount of medical treatment 
needed.  
 
There is minimal if any correlation between the difference in program medical 
cost and the reduction of A1C participant values. Based on the statistical analysis, the 
efforts of the diabetes workplace wellness program did not result in a statistical 
difference or correlation between the cost difference and change in participant A1C 
values. This indicates that the change in cost, whether as an increase or decrease, from 
pre- to post-program did not provide influence on the improvement of the A1C values for 
the study group. Based on the program evaluation being a twelve month period, the A1C 
value appears to be more related to the impact of the health coaches than the change in 
cost associated with the medical care. Based on the improved health behaviors of the 
participants, the medical cost savings is more an indication of patient engagement.  
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The third most significant finding of this project is the evaluation of the pre- and 
post-program weight and ACO risk score. The twenty-eight participants had a mean pre-
program weight of 269 pounds. Over the twelve month period the program group 
increased the mean weight to 271 pounds, though not statistically significant. This was 
not an expected outcome based on the utilization of health coaches to assist each 
participant with adjusting behaviors to better manage their diabetes. In addition to the 
health coaches, each participant received program incentives that eliminated barriers to a 
healthier lifestyle. These incentives included appropriate exercise footwear, gym 
membership, and pedometers. While these incentives appeared to be of benefit during the 
first quarter of the program, there utilization appeared to decline over the twelve month 
program. By evaluating the quarterly step data tracked on the participant’s pedometers, 
the mean daily average number of steps decreased by over 2,000 steps from the 
beginning of the program to final quarter of the twelve month period. The recommended 
daily average step count goal is 10,000 steps a day and the program participants 
cumulative daily average step count was under 7,000 steps in quarter one and declined to 
less than 5,000 steps in quarter four of the twelve month program. This result assists in 
explaining why the program participant’s weight remained relatively unchanged as part 
of the part of the workplace wellness program.  
 
The ACO risk scores calculated using the CCMS tool, pre- and post-program, 
were compared to determine if the reduction in medical cost and increase in 
pharmaceutical cost had an impact on the participant risk scores. As reported in the 
results section, the mean risk scores of program participants only changed by 0.26 over 
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the twelve month program. Since the risk scores are directly related to the overall health 
care cost for each participant, minimal change in the mean risk score aligns with the 
marginal change in the total medical and pharmaceutical cost recorded for the program 
participants. As with the weight evaluation, the results of a two-tailed T-Test comparing 
risk scores did not determine a statistical difference. What is interesting, is the risk score 
saw little change as a result of the program even though the A1C values for the program 
are statistically different. This is an indication why evaluating a patient’s health solely 
based on cost may not be the most accurate method and that even though the cost for the 
twenty-eight program participants to receive medical and pharmaceutical care did not 
have a significant savings the overall value used to assess diabetes, A1C, did improve. As 
reimbursement within the health care industry continues to be more restrictive, the 
industry is become much more cost conscious. Eliminating wasteful spending in health 
care is the correct direction and is part of accountable care policy. That being said, health 
care is not an industry of “widget making” and should be evaluated from multiple 
disciplines such as finance, clinical efficiency, and quality of care received. By 
evaluating one of these, such as finance, without consideration of the other two could 
result in the improvement of the specific discipline at the expense of inefficient clinical 
practice or poor quality outcomes for the patient. The other challenge of evaluating the 
true impact of this study is the unknown cost avoidance for the twenty-eight participants. 
Determining if the diabetes workplace wellness program prevented more costly care, 
such as hospitalization due to acute ketoacidosis, would require data collection over a 
longer period of time to apply national diabetes trending data in comparison to the care 
required to the twenty-eight participants. 
90 
 
Diabetes is reported as consuming one in every ten health care dollars in the 
United States. That translates to the cost of care associated with diabetes accounts for 
over a trillion dollars a year. For this reason, many health care providers understand the 
value of reducing the cost associated with caring for patients with diabetes and finding 
ways to reduce the number of new diabetes diagnoses on an annual basis. As discussed 
previously, the ACO model attempts to achieve better engagement by individuals in 
maintaining good health and reducing the expense of services needed when health care is 
necessary.  
 
The fourth significant finding of this research is the negative results of the 
financial evaluation, specifically for the CBA and ROI of the diabetes workplace 
wellness program. The CBA is a basic calculation used to determine if the total costs for 
the diabetes workplace wellness program were lesser or greater than the total cost of 
providing medical and pharmaceutical care to the twenty-eight program participants. As 
reported in the Results section, the CBA Total was a loss at -$779,625.55 for the 
program. The pre-program cost, which was the total medical and pharmaceutical expense, 
for the participants was $267,429.99. The total cost for the diabetes workplace wellness 
program, which included program personnel, software expense, incentive expense, and 
total health care costs, was $1,047,055.54. For a positive CBA to occur the total program 
expense would have needed to be less than $267,000.00 within the first year. Adding the 
commercial ACO software and health coach staff made it very difficult to achieve a 
positive CBA. Both of these program components cost, ACO software and staff, cost the 
program $573,640.64 and $117,944.00, respectively. Removing those two program 
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expenses would have resulted in a negative CBA of -$88,040.91 for the first year of the 
program. While the cost of the health coach staff and commercial software had a 
significant impact on the overall CBA, it would be difficult to eliminate both of these 
components of the program. The health coach employees worked directly with the 
patients to eliminate barriers to receiving appropriate care and drive higher engagement 
and responsibility by the participants. Without the health coach involvement, the A1C 
values may not have improved as they did over the twelve month program. The 
commercial software expense is an unfortunate reality of health care information 
technology. The health care industry is very expensive and the non-direct patient care 
tools used are no exception. The software utilized in health care is very expensive and 
should be an area of focus for information technology professionals. As new software is 
being considered for purchase, information technology professionals should first evaluate 
what the return on investment will be by adding new tools. In many cases, software is 
purchased solely on new functionality with little consideration of how net revenues will 
be improved. If software is purchased without the financial analysis, the additional 
functionality could easily have a negative impact on the net revenue for the organization 
which could lead to increased fees for services to maintain operating margins. Once it is 
determined that the new functionality will be beneficial to clinical efficiency, quality 
outcomes, and organizational finances, information technology leaders should find ways 
to reduce duplication of products and identify the best pricing to avoid utilizing capital 
that is best spent on direct patient care tools. These types of expenses all relate back to 
the overwhelming expense patients incur when receiving care in the current health care 
model.   
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The ROI for the diabetes workplace wellness program has similar results to the 
CBA calculation. The ROI calculation is a formula that compares the investment gain and 
investment cost to determine if the program provided a positive or negative return on the 
funds invested to initiate the program. With the investment cost being so much greater 
than the investment gain in the twelve months of the program, it is not a surprise that the 
program had a – 99% ROI. As it was explained with the CBA results, the capital expense 
of adding the commercial ACO software and the staffing expense significantly reduced 
the ability of the program to generate a positive ROI. That coupled with the cost savings 
for medical and pharmaceutical expense only totaling $6,879.09, a negative ROI is to be 
expected. As mentioned previously, estimating the ROI of new information technology 
solutions should be completed prior to purchase and implementation of the product. In 
the new health care reimbursement model, all payers in the industry are reducing the 
reimbursement for care provided and hold health care organizations accountable for 
finding cost savings. At the same time health care legislation is challenging organizations 
to be more transparent with price and quality which requires new systems and services to 
be put in place, such as diabetes workplace wellness programs. The challenge of this 
model is the funding for service expansion is being reduced while capital investments are 
being increased. The diabetes workplace wellness program reviewed in this research has 
demonstrated an improvement in participant A1C values within the first twelve months of 
the program which is a success. The negative ROI indicates more money was spent than 
saved but typically ROI’s are determined over a much longer period of time allowing for 
increased savings to offset the initial expense of establishing the program. Even after 
expanding the program via the sensitivity analysis, which allowed for greater program 
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time and more participants, only improved the ROI to -94%. Only by eliminating the 
program incentive expense over a five year period with program participant growth 
resulted in a positive ROI of 11%. Using the ROI calculation listed above could be 
considered too harsh of an evaluation for the purposes of this research, but using a 
financial ROI evaluation is a reality of the current health care industry. Not all processes 
in health care are driven by financial evaluations but ignoring these types of evaluations 
has a potential for greater impact than anticipated. 
  
Limitations of the research associated with the diabetes workplace wellness 
program range from a small participant population to assuming the cost of a commercial 
ACO risk tool in the first year. The population used for the program originally was slated 
for fifty participants from a single organization but was reduced to twenty-eight 
participants due to a lack of data or failure of the participant to enroll. The fact that a 
small population from a single organization was used makes it difficult to generalize the 
findings. Most of the research reviewed in preparation for this project used populations 
that numbered in the tens to hundreds of thousands and were mostly focused on 
workplace wellness programs without ACO software. When considering the sample size 
of the research, it is almost important to note the impact of the law of large numbers and 
how a greater participant population would have an impact on the results of similar 
research. A second limitation was the program was developed as a pilot to assess the 
benefit of the ACO software in combination with a workplace wellness program. While 
pilots are beneficial to perform initial evaluations, that are also usually the first effort to 
develop processes and procedures. Developing the functionality of the program at the 
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same time of evaluating the program resulted in unexpected issues that would impact the 
outcome of the program such as adding or removing participants of the program to 
maintain the original program population. A third limitation, was the length of the study. 
Twelve months for a financial evaluation of a small population is challenging. Especially 
when the majority of program expenses are incurred in the first twelve months. Not 
accounting for the deflation or inflation of costs over the twelve month period is the 
fourth limitation and it should be noted that the costs of the medical and pharmaceutical 
care were realized and not observed. The fifth and possibly greatest limitation to the 
program was the cost of the commercially ACO software. Utilizing a fully functional, 
large population tool to assess the risk of a small population created excessive financial 
burden on both the CBA and ROI analysis. 
 
Future research that should be attempted based on the findings of this project 
would be to evaluate the financial outcome of an identical project with a much larger 
population over a five year time frame. The five year time frame is the standard length of 
time to fully expense capital software purchases versus assessing the total software cost 
in the first year. Additionally, it would be interesting to understanding if a program based 
on increased pharmaceutical care for diabetics would provide the same benefit as this 
diabetes workplace wellness program. Based on the results of the program, it appears that 
the increase in pharmaceutical expense reduced the medical expense for the participants 
of the program and the overall A1C. This may be an artifact of the limited population size 




In conclusion, the answer to the research question, “Can using an ACO 
commercially available software tool and a diabetes workplace wellness management 
program be combined to identify 1 year ROI in a sample of patients within an average 
size institution?” is yes, it was possible to calculate an ROI but resulted in a negative 
return on investment. The research hypothesis, “Utilizing the tools provided with both 
commercially available ACO software and workplace wellness program structure, the 
cost associated with managing the health care of individuals diagnosed with diabetes will 
be reduced” must be rejected based on both the negative CBA and ROI results. That 
being said, understanding the dramatic impact diabetes has on individuals diagnosed with 
the disease, health care resources, and overall expense to the health care system, this 
research provides evidence that the ACO model combined with a workplace wellness 
program does address the impact on the individual by improving the management of the 
disease, as seen by the reduction in A1C values, and reduces the burden on health care 
resources by reducing the need for medical care by properly utilizing pharmaceutical care 
to manage the individual’s diabetes. The program results also demonstrate that to 
positively impact the financial burden on the health care system, the ACO model is a long 
term proposition that requires substantial and continuous effort to modify the behaviors 
of individuals and increase their engagement in preventative care versus episodic care. 
Being able to move the A1C value in the right direction is the greatest success of this 
research. It is important that even though the financial evaluations of the program 
indicate a less than positive result, I believe this is more a reflection of the length of time 
and size of population of the program than determinant of program value.   
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